mirror of
https://github.com/msberends/AMR.git
synced 2026-11-16 00:10:57 +01:00
dr. M.S. (Matthijs) Berends
414f41ba22
The rebuild uses the WHONET files of today, and holds the changes of #326, #327, #328, #329 and #331. The files in data-raw/datasets are not regenerated yet.
6.6 MiB
6.6 MiB
| 1 | guideline | version | file_desc | type | host | method | site | mo | table_organism | rank_index | ab | disk_dose | breakpoint_S | breakpoint_R | source_S | source_R | is_bracketed | note | sheet |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Benzylpenicillin | NA | - | - | B10 | C10 | FALSE | NA | Enterobacterales |
| 3 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Benzylpenicillin | NA | - | - | F10 | G10 | FALSE | NA | Enterobacterales |
| 4 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ampicillin | NA | 8 | 8 | B11 | C11 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | Enterobacterales |
| 5 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ampicillin | 10 mcg | 14 | 14 | F11 | G11 | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 6 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ampicillin-sulbactam | NA | 8 | 8 | B12 | C12 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | Enterobacterales |
| 7 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ampicillin-sulbactam | 10/10 mcg | 14 | 14 | F12 | G12 | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 8 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Amoxicillin | NA | 8 | 8 | B13 | C13 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | Enterobacterales |
| 9 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Amoxicillin | / mcg | Note | Note | F13 | G13 | FALSE | [C] Susceptibility inferred from ampicillin. | Enterobacterales |
| 10 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Amoxicillin-clavulanic acid | NA | 8 | 8 | B14 | C14 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 11 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Amoxicillin-clavulanic acid | 20/10 mcg | 19 | 19 | F14 | G14 | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 12 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | NA | 32 | 32 | B15 | C15 | FALSE | [1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 13 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Amoxicillin-clavulanic acid (uncomplicated UTI only) | 20/10 mcg | 16 | 16 | F15 | G15 | FALSE | [A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as "Susceptible, increased exposure". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | Enterobacterales |
| 14 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Piperacillin | NA | 8 | 16 | B16 | C16 | FALSE | NA | Enterobacterales |
| 15 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Piperacillin | 30 mcg | 20 | 17 | F16 | G16 | FALSE | NA | Enterobacterales |
| 16 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Piperacillin-tazobactam | NA | 8 | 16 | B17 | C17 | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 17 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Piperacillin-tazobactam | 30/6 mcg | 20 | 17 | F17 | G17 | FALSE | NA | Enterobacterales |
| 18 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ticarcillin | NA | 8 | 16 | B18 | C18 | FALSE | NA | Enterobacterales |
| 19 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ticarcillin | 75 mcg | 23 | 20 | F18 | G18 | FALSE | NA | Enterobacterales |
| 20 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ticarcillin-clavulanic acid | NA | 8 | 16 | B19 | C19 | FALSE | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | Enterobacterales |
| 21 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ticarcillin-clavulanic acid | 75/10 mcg | 23 | 20 | F19 | G19 | FALSE | NA | Enterobacterales |
| 22 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Temocillin | NA | Note | Note | B20 | C20 | FALSE | [5] Breakpoints still under consideration. | Enterobacterales |
| 23 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Temocillin | NA | Note | Note | F20 | G20 | FALSE | [5] Breakpoints still under consideration. | Enterobacterales |
| 24 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Phenoxymethylpenicillin | NA | - | - | B22 | C22 | FALSE | NA | Enterobacterales |
| 25 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Phenoxymethylpenicillin | NA | - | - | F22 | G22 | FALSE | NA | Enterobacterales |
| 26 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Oxacillin | NA | - | - | B24 | C24 | FALSE | NA | Enterobacterales |
| 27 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Oxacillin | NA | - | - | F24 | G24 | FALSE | NA | Enterobacterales |
| 28 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cloxacillin | NA | - | - | B25 | C25 | FALSE | NA | Enterobacterales |
| 29 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cloxacillin | NA | - | - | F25 | G25 | FALSE | NA | Enterobacterales |
| 30 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Dicloxacillin | NA | - | - | B26 | C26 | FALSE | NA | Enterobacterales |
| 31 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Dicloxacillin | NA | - | - | F26 | G26 | FALSE | NA | Enterobacterales |
| 32 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Flucloxacillin | NA | - | - | B27 | C27 | FALSE | NA | Enterobacterales |
| 33 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Flucloxacillin | NA | - | - | F27 | G27 | FALSE | NA | Enterobacterales |
| 34 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | Mecillinam (uncomplicated UTI only) | NA | 8 | 8 | B29 | C29 | FALSE | [6] Agar dilution is the reference method for mecillinam MIC determination. | Enterobacterales |
| 35 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | Mecillinam (uncomplicated UTI only) | 10 mcg | 15 | 15 | F29 | G29 | FALSE | [D] Ignore isolated colonies within the inhibition zone for E. coli. | Enterobacterales |
| 36 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cefaclor | NA | - | - | B34 | C34 | FALSE | NA | Enterobacterales |
| 37 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cefaclor | NA | - | - | F34 | G34 | FALSE | NA | Enterobacterales |
| 38 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | NA | 16 | 16 | B35 | C35 | FALSE | NA | Enterobacterales |
| 39 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cefadroxil (uncomplicated UTI only) | 30 mcg | 12 | 12 | F35 | G35 | FALSE | NA | Enterobacterales |
| 40 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | NA | 16 | 16 | B36 | C36 | FALSE | NA | Enterobacterales |
| 41 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cefalexin (uncomplicated UTI only) | 30 mcg | 14 | 14 | F36 | G36 | FALSE | NA | Enterobacterales |
| 42 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cefazolin | NA | - | - | B37 | C37 | FALSE | NA | Enterobacterales |
| 43 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cefazolin | NA | - | - | F37 | G37 | FALSE | NA | Enterobacterales |
| 44 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cefepime | NA | 1 | 4 | B38 | C38 | FALSE | NA | Enterobacterales |
| 45 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cefepime | 30 mcg | 27 | 24 | F38 | G38 | FALSE | NA | Enterobacterales |
| 46 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | NA | 1 | 1 | B39 | C39 | FALSE | NA | Enterobacterales |
| 47 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cefixime (uncomplicated UTI only) | 5 mcg | 17 | 17 | F39 | G39 | FALSE | NA | Enterobacterales |
| 48 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cefotaxime | NA | 1 | 2 | B40 | C40 | FALSE | NA | Enterobacterales |
| 49 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cefotaxime | 5 mcg | 20 | 17 | F40 | G40 | FALSE | NA | Enterobacterales |
| 50 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cefoxitin (screen) | NA | NA | NA | B41 | C41 | FALSE | [2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type. | Enterobacterales |
| 51 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cefoxitin (screen) | 30 mcg | 19 | 19 | F41 | G41 | FALSE | [2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type. | Enterobacterales |
| 52 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | NA | 1 | 1 | B42 | C42 | FALSE | NA | Enterobacterales |
| 53 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Cefpodoxime (uncomplicated UTI only) | 10 mcg | 21 | 21 | F42 | G42 | FALSE | NA | Enterobacterales |
| 54 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ceftaroline | NA | 0.5 | 0.5 | B43 | C43 | FALSE | NA | Enterobacterales |
| 55 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ceftaroline | 5 mcg | 23 | 23 | F43 | G43 | FALSE | NA | Enterobacterales |
| 56 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ceftazidime | NA | 1 | 4 | B44 | C44 | FALSE | NA | Enterobacterales |
| 57 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ceftazidime | 10 mcg | 22 | 19 | F44 | G44 | FALSE | NA | Enterobacterales |
| 58 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ceftazidime-avibactam | NA | 8 | 8 | B45 | C45 | FALSE | [3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Enterobacterales |
| 59 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ceftazidime-avibactam | 10/4 mcg | 13 | 13 | F45 | G45 | FALSE | NA | Enterobacterales |
| 60 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ceftibuten (UTI only) | NA | 1 | 1 | B46 | C46 | FALSE | NA | Enterobacterales |
| 61 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ceftibuten (UTI only) | 30 mcg | 23 | 23 | F46 | G46 | FALSE | NA | Enterobacterales |
| 62 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ceftobiprole | NA | 0.25 | 0.25 | B47 | C47 | FALSE | NA | Enterobacterales |
| 63 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ceftobiprole | 5 mcg | 23 | 23 | F47 | G47 | FALSE | NA | Enterobacterales |
| 64 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ceftolozane-tazobactam | NA | 1 | 1 | B48 | C48 | FALSE | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Enterobacterales |
| 65 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ceftolozane-tazobactam | 30/10 mcg | 23 | 23 | F48 | G48 | FALSE | NA | Enterobacterales |
| 66 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ceftriaxone | NA | 1 | 2 | B49 | C49 | FALSE | NA | Enterobacterales |
| 67 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ceftriaxone | 30 mcg | 25 | 22 | F49 | G49 | FALSE | NA | Enterobacterales |
| 68 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | Cefuroxime iv | NA | 8 | 8 | B50 | C50 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 69 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | Cefuroxime iv | 30 mcg | 19 | 19 | F50 | G50 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 70 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | Cefuroxime oral (uncomplicated UTI only) | NA | 8 | 8 | B51 | C51 | FALSE | NA | Enterobacterales |
| 71 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis | Enterobacterales | NA | Cefuroxime oral (uncomplicated UTI only) | 30 mcg | 19 | 19 | F51 | G51 | FALSE | NA | Enterobacterales |
| 72 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ertapenem | NA | 0.5 | 0.5 | B57 | C57 | FALSE | NA | Enterobacterales |
| 73 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ertapenem | 10 mcg | 25 | 25 | F57 | G57 | FALSE | NA | Enterobacterales |
| 74 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Imipenem | NA | 2 | 4 | B58 | C58 | FALSE | NA | Enterobacterales |
| 75 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Imipenem | 10 mcg | 22 | 17 | F58 | G58 | FALSE | NA | Enterobacterales |
| 76 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Morganella morganii,Proteus spp. and Providencia spp. | Enterobacterales | NA | Imipenem | NA | 0.125 | 4 | B59 | C59 | FALSE | [2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem. | Enterobacterales |
| 77 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Morganella morganii,Proteus spp. and Providencia spp. | Enterobacterales | NA | Imipenem | 10 mcg | 50 | 17 | F59 | G59 | FALSE | [2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem. | Enterobacterales |
| 78 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Meropenem | NA | 2 | 8 | B60 | C60 | FALSE | NA | Enterobacterales |
| 79 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Meropenem | 10 mcg | 22 | 16 | F60 | G60 | FALSE | NA | Enterobacterales |
| 80 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Meropenem-vaborbactam | NA | 8 | 8 | B61 | C61 | FALSE | [3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Enterobacterales |
| 81 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Meropenem-vaborbactam | IP mcg | IP | IP | F61 | G61 | FALSE | NA | Enterobacterales |
| 82 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Aztreonam | NA | 1 | 4 | B66 | C66 | FALSE | [1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes. | Enterobacterales |
| 83 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Aztreonam | 30 mcg | 26 | 21 | F66 | G66 | FALSE | [1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes. | Enterobacterales |
| 84 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ciprofloxacin | NA | 0.25 | 0.5 | B71 | C71 | FALSE | NA | Enterobacterales |
| 85 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ciprofloxacin | 5 mcg | 25 | 22 | F71 | G71 | FALSE | NA | Enterobacterales |
| 86 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Salmonella spp. | Enterobacterales | NA | Ciprofloxacin | NA | 0.06 | 0.06 | B72 | C72 | FALSE | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 87 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Salmonella spp. | Enterobacterales | NA | Ciprofloxacin | NA | Note | Note | F72 | G72 | FALSE | [A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note B. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 88 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Salmonella spp. | Enterobacterales | NA | Pefloxacin (screen) | NA | NA | NA | B73 | C73 | FALSE | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 89 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Salmonella spp. | Enterobacterales | NA | Pefloxacin (screen) | 5 mcg | 24 | 24 | F73 | G73 | FALSE | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | Enterobacterales |
| 90 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Levofloxacin | NA | 0.5 | 1 | B74 | C74 | FALSE | NA | Enterobacterales |
| 91 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Levofloxacin | 5 mcg | 23 | 19 | F74 | G74 | FALSE | NA | Enterobacterales |
| 92 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Moxifloxacin | NA | 0.25 | 0.25 | B75 | C75 | FALSE | NA | Enterobacterales |
| 93 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Moxifloxacin | 5 mcg | 22 | 22 | F75 | G75 | FALSE | NA | Enterobacterales |
| 94 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Nalidixic acid (screen) | NA | NA | NA | B76 | C76 | FALSE | NA | Enterobacterales |
| 95 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Nalidixic acid (screen) | NA | NA | NA | F76 | G76 | FALSE | NA | Enterobacterales |
| 96 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | NA | 0.5 | 1 | B77 | C77 | FALSE | NA | Enterobacterales |
| 97 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Norfloxacin (uncomplicated UTI only) | 10 mcg | 22 | 19 | F77 | G77 | FALSE | NA | Enterobacterales |
| 98 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Ofloxacin | NA | 0.25 | 0.5 | B78 | C78 | FALSE | NA | Enterobacterales |
| 99 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Ofloxacin | 5 mcg | 24 | 22 | F78 | G78 | FALSE | NA | Enterobacterales |
| 100 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Amikacin | NA | 8 | 16 | B83 | C83 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 101 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Amikacin | 30 mcg | 18 | 15 | F83 | G83 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 102 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Gentamicin | NA | 2 | 4 | B84 | C84 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 103 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Gentamicin | 10 mcg | 17 | 14 | F84 | G84 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 104 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Netilmicin | NA | 2 | 4 | B85 | C85 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 105 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Netilmicin | 10 mcg | 15 | 12 | F85 | G85 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 106 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Tobramycin | NA | 2 | 4 | B86 | C86 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 107 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Tobramycin | 10 mcg | 17 | 14 | F86 | G86 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Enterobacterales |
| 108 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Dalbavancin | NA | - | - | B91 | C91 | FALSE | NA | Enterobacterales |
| 109 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Dalbavancin | NA | - | - | F91 | G91 | FALSE | NA | Enterobacterales |
| 110 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Oritavancin | NA | - | - | B92 | C92 | FALSE | NA | Enterobacterales |
| 111 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Oritavancin | NA | - | - | F92 | G92 | FALSE | NA | Enterobacterales |
| 112 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Teicoplanin | NA | - | - | B93 | C93 | FALSE | NA | Enterobacterales |
| 113 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Teicoplanin | NA | - | - | F93 | G93 | FALSE | NA | Enterobacterales |
| 114 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Telavancin | NA | - | - | B94 | C94 | FALSE | NA | Enterobacterales |
| 115 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Telavancin | NA | - | - | F94 | G94 | FALSE | NA | Enterobacterales |
| 116 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Vancomycin | NA | - | - | B95 | C95 | FALSE | NA | Enterobacterales |
| 117 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Vancomycin | NA | - | - | F95 | G95 | FALSE | NA | Enterobacterales |
| 118 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Azithromycin | NA | - | - | B100 | C100 | FALSE | [1] Azithromycin has been used in the treatment of infections with Salmonella Typhi (MIC ≤16 mg/L for wild-type isolates) and Shigella spp. | Enterobacterales |
| 119 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Azithromycin | NA | - | - | F100 | G100 | FALSE | [1] Azithromycin has been used in the treatment of infections with Salmonella Typhi (MIC ≤16 mg/L for wild-type isolates) and Shigella spp. | Enterobacterales |
| 120 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Clarithromycin | NA | - | - | B101 | C101 | FALSE | NA | Enterobacterales |
| 121 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Clarithromycin | NA | - | - | F101 | G101 | FALSE | NA | Enterobacterales |
| 122 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Erythromycin | NA | - | - | B102 | C102 | FALSE | NA | Enterobacterales |
| 123 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Erythromycin | NA | - | - | F102 | G102 | FALSE | NA | Enterobacterales |
| 124 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Roxithromycin | NA | - | - | B103 | C103 | FALSE | NA | Enterobacterales |
| 125 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Roxithromycin | NA | - | - | F103 | G103 | FALSE | NA | Enterobacterales |
| 126 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Telithromycin | NA | - | - | B104 | C104 | FALSE | NA | Enterobacterales |
| 127 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Telithromycin | NA | - | - | F104 | G104 | FALSE | NA | Enterobacterales |
| 128 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Clindamycin | NA | - | - | B106 | C106 | FALSE | NA | Enterobacterales |
| 129 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Clindamycin | NA | - | - | F106 | G106 | FALSE | NA | Enterobacterales |
| 130 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Quinupristin-dalfopristin | NA | - | - | B107 | C107 | FALSE | NA | Enterobacterales |
| 131 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Quinupristin-dalfopristin | NA | - | - | F107 | G107 | FALSE | NA | Enterobacterales |
| 132 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Doxycycline | NA | - | - | B112 | C112 | FALSE | NA | Enterobacterales |
| 133 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Doxycycline | NA | - | - | F112 | G112 | FALSE | NA | Enterobacterales |
| 134 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli | Enterobacterales | NA | Eravacycline | NA | 0.5 | 0.5 | B113 | C113 | FALSE | NA | Enterobacterales |
| 135 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli | Enterobacterales | NA | Eravacycline | IP mcg | IP | IP | F113 | G113 | FALSE | NA | Enterobacterales |
| 136 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Minocycline | NA | - | - | B114 | C114 | FALSE | NA | Enterobacterales |
| 137 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Minocycline | NA | - | - | F114 | G114 | FALSE | NA | Enterobacterales |
| 138 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Tetracycline | NA | - | - | B115 | C115 | FALSE | [1] Tetracycline has been used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC ≤4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 µg disk is ≥19 mm. | Enterobacterales |
| 139 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Tetracycline | NA | - | - | F115 | G115 | FALSE | [1] Tetracycline has been used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC ≤4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 µg disk is ≥19 mm. | Enterobacterales |
| 140 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli and C. koseri | Enterobacterales | NA | Tigecycline | NA | 0.5 | 0.5 | B116 | C116 | FALSE | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | Enterobacterales |
| 141 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli and C. koseri | Enterobacterales | NA | Tigecycline | 15 mcg | 18 | 18 | F116 | G116 | FALSE | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method. | Enterobacterales |
| 142 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Linezolid | NA | - | - | B121 | C121 | FALSE | NA | Enterobacterales |
| 143 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Linezolid | NA | - | - | F121 | G121 | FALSE | NA | Enterobacterales |
| 144 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Tedizolid | NA | - | - | B122 | C122 | FALSE | NA | Enterobacterales |
| 145 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Tedizolid | NA | - | - | F122 | G122 | FALSE | NA | Enterobacterales |
| 146 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Chloramphenicol | NA | 8 | 8 | B127 | C127 | FALSE | NA | Enterobacterales |
| 147 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Chloramphenicol | 30 mcg | 17 | 17 | F127 | G127 | FALSE | NA | Enterobacterales |
| 148 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Colistin | NA | 2 | 2 | B128 | C128 | FALSE | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Enterobacterales |
| 149 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Colistin | NA | Note | Note | F128 | G128 | FALSE | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Enterobacterales |
| 150 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Daptomycin | NA | - | - | B129 | C129 | FALSE | NA | Enterobacterales |
| 151 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Daptomycin | NA | - | - | F129 | G129 | FALSE | NA | Enterobacterales |
| 152 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Fosfomycin iv | NA | 32 | 32 | B130 | C130 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | Enterobacterales |
| 153 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Fosfomycin iv | 200 mcg | 24 | 24 | F130 | G130 | FALSE | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 154 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | NA | 32 | 32 | B131 | C131 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | Enterobacterales |
| 155 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Fosfomycin oral (uncomplicated UTI only) | 200 mcg | 24 | 24 | F131 | G131 | FALSE | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below). | Enterobacterales |
| 156 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Fusidic acid | NA | - | - | B132 | C132 | FALSE | NA | Enterobacterales |
| 157 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Fusidic acid | NA | - | - | F132 | G132 | FALSE | NA | Enterobacterales |
| 158 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Metronidazole | NA | - | - | B133 | C133 | FALSE | NA | Enterobacterales |
| 159 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Metronidazole | NA | - | - | F133 | G133 | FALSE | NA | Enterobacterales |
| 160 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli | Enterobacterales | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | B134 | C134 | FALSE | NA | Enterobacterales |
| 161 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli | Enterobacterales | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 11 | 11 | F134 | G134 | FALSE | NA | Enterobacterales |
| 162 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. coli | Enterobacterales | NA | Nitroxoline (uncomplicated UTI only) | NA | 16 | 16 | B135 | C135 | FALSE | NA | Enterobacterales |
| 163 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. coli | Enterobacterales | NA | Nitroxoline (uncomplicated UTI only) | 30 mcg | 15 | 15 | F135 | G135 | FALSE | NA | Enterobacterales |
| 164 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Rifampicin | NA | - | - | B136 | C136 | FALSE | NA | Enterobacterales |
| 165 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Rifampicin | NA | - | - | F136 | G136 | FALSE | NA | Enterobacterales |
| 166 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Spectinomycin | NA | - | - | B137 | C137 | FALSE | NA | Enterobacterales |
| 167 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Spectinomycin | NA | - | - | F137 | G137 | FALSE | NA | Enterobacterales |
| 168 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | NA | 2 | 4 | B138 | C138 | FALSE | NA | Enterobacterales |
| 169 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | 18 | 15 | F138 | G138 | FALSE | NA | Enterobacterales |
| 170 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterobacterales | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | NA | 2 | 4 | B139 | C139 | FALSE | [3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterobacterales |
| 171 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterobacterales | Enterobacterales | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 14 | 11 | F139 | G139 | FALSE | [3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterobacterales |
| 172 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Benzylpenicillin | NA | - | - | B10 | C10 | FALSE | NA | Pseudomonas |
| 173 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Benzylpenicillin | NA | - | - | F10 | G10 | FALSE | NA | Pseudomonas |
| 174 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ampicillin | NA | - | - | B11 | C11 | FALSE | NA | Pseudomonas |
| 175 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ampicillin | NA | - | - | F11 | G11 | FALSE | NA | Pseudomonas |
| 176 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ampicillin-sulbactam | NA | - | - | B12 | C12 | FALSE | NA | Pseudomonas |
| 177 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ampicillin-sulbactam | NA | - | - | F12 | G12 | FALSE | NA | Pseudomonas |
| 178 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Amoxicillin | NA | - | - | B13 | C13 | FALSE | NA | Pseudomonas |
| 179 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Amoxicillin | NA | - | - | F13 | G13 | FALSE | NA | Pseudomonas |
| 180 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Amoxicillin-clavulanic acid | NA | - | - | B14 | C14 | FALSE | NA | Pseudomonas |
| 181 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Amoxicillin-clavulanic acid | NA | - | - | F14 | G14 | FALSE | NA | Pseudomonas |
| 182 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Piperacillin | NA | 16 | 16 | B15 | C15 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 183 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Piperacillin | 30 mcg | 18 | 18 | F15 | G15 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 184 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Piperacillin-tazobactam | NA | 16 | 16 | B16 | C16 | FALSE | [1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 185 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Piperacillin-tazobactam | 30/6 mcg | 18 | 18 | F16 | G16 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 186 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ticarcillin | NA | 16 | 16 | B17 | C17 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 187 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ticarcillin | 75 mcg | 18 | 18 | F17 | G17 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 188 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | NA | 16 | 16 | B18 | C18 | FALSE | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 189 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ticarcillin-clavulanic acid | 75/10 mcg | 18 | 18 | F18 | G18 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 190 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Temocillin | NA | - | - | B19 | C19 | FALSE | NA | Pseudomonas |
| 191 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Temocillin | NA | - | - | F19 | G19 | FALSE | NA | Pseudomonas |
| 192 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Phenoxymethylpenicillin | NA | - | - | B21 | C21 | FALSE | NA | Pseudomonas |
| 193 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Phenoxymethylpenicillin | NA | - | - | F21 | G21 | FALSE | NA | Pseudomonas |
| 194 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Oxacillin | NA | - | - | B23 | C23 | FALSE | NA | Pseudomonas |
| 195 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Oxacillin | NA | - | - | F23 | G23 | FALSE | NA | Pseudomonas |
| 196 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cloxacillin | NA | - | - | B24 | C24 | FALSE | NA | Pseudomonas |
| 197 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cloxacillin | NA | - | - | F24 | G24 | FALSE | NA | Pseudomonas |
| 198 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Dicloxacillin | NA | - | - | B25 | C25 | FALSE | NA | Pseudomonas |
| 199 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Dicloxacillin | NA | - | - | F25 | G25 | FALSE | NA | Pseudomonas |
| 200 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Flucloxacillin | NA | - | - | B26 | C26 | FALSE | NA | Pseudomonas |
| 201 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Flucloxacillin | NA | - | - | F26 | G26 | FALSE | NA | Pseudomonas |
| 202 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B28 | C28 | FALSE | NA | Pseudomonas |
| 203 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | F28 | G28 | FALSE | NA | Pseudomonas |
| 204 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefaclor | NA | - | - | B33 | C33 | FALSE | NA | Pseudomonas |
| 205 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefaclor | NA | - | - | F33 | G33 | FALSE | NA | Pseudomonas |
| 206 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefadroxil | NA | - | - | B34 | C34 | FALSE | NA | Pseudomonas |
| 207 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefadroxil | NA | - | - | F34 | G34 | FALSE | NA | Pseudomonas |
| 208 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefalexin | NA | - | - | B35 | C35 | FALSE | NA | Pseudomonas |
| 209 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefalexin | NA | - | - | F35 | G35 | FALSE | NA | Pseudomonas |
| 210 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefazolin | NA | - | - | B36 | C36 | FALSE | NA | Pseudomonas |
| 211 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefazolin | NA | - | - | F36 | G36 | FALSE | NA | Pseudomonas |
| 212 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefepime | NA | 8 | 8 | B37 | C37 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 213 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefepime | 30 mcg | 21 | 21 | F37 | G37 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 214 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefixime | NA | - | - | B38 | C38 | FALSE | NA | Pseudomonas |
| 215 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefixime | NA | - | - | F38 | G38 | FALSE | NA | Pseudomonas |
| 216 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefotaxime | NA | - | - | B39 | C39 | FALSE | NA | Pseudomonas |
| 217 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefotaxime | NA | - | - | F39 | G39 | FALSE | NA | Pseudomonas |
| 218 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefoxitin | NA | NA | NA | B40 | C40 | FALSE | NA | Pseudomonas |
| 219 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefoxitin | NA | NA | NA | F40 | G40 | FALSE | NA | Pseudomonas |
| 220 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefpodoxime | NA | - | - | B41 | C41 | FALSE | NA | Pseudomonas |
| 221 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefpodoxime | NA | - | - | F41 | G41 | FALSE | NA | Pseudomonas |
| 222 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftaroline | NA | - | - | B42 | C42 | FALSE | NA | Pseudomonas |
| 223 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftaroline | NA | - | - | F42 | G42 | FALSE | NA | Pseudomonas |
| 224 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftazidime | NA | 8 | 8 | B43 | C43 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 225 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftazidime | 10 mcg | 17 | 17 | F43 | G43 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 226 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | P. aeruginosa | Pseudomonas spp. | NA | Ceftazidime-avibactam | NA | 8 | 8 | B44 | C44 | FALSE | [1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L. | Pseudomonas |
| 227 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | P. aeruginosa | Pseudomonas spp. | NA | Ceftazidime-avibactam | 10/4 mcg | 17 | 17 | F44 | G44 | FALSE | NA | Pseudomonas |
| 228 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftibuten | NA | - | - | B45 | C45 | FALSE | NA | Pseudomonas |
| 229 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftibuten | NA | - | - | F45 | G45 | FALSE | NA | Pseudomonas |
| 230 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftobiprole | NA | IE | IE | B46 | C46 | FALSE | NA | Pseudomonas |
| 231 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftobiprole | NA | IE | IE | F46 | G46 | FALSE | NA | Pseudomonas |
| 232 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | P. aeruginosa | Pseudomonas spp. | NA | Ceftolozane-tazobactam | NA | 4 | 4 | B47 | C47 | FALSE | [2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | Pseudomonas |
| 233 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | P. aeruginosa | Pseudomonas spp. | NA | Ceftolozane-tazobactam | 30/10 mcg | 24 | 24 | F47 | G47 | FALSE | NA | Pseudomonas |
| 234 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftriaxone | NA | - | - | B48 | C48 | FALSE | NA | Pseudomonas |
| 235 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ceftriaxone | NA | - | - | F48 | G48 | FALSE | NA | Pseudomonas |
| 236 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefuroxime iv | NA | - | - | B49 | C49 | FALSE | NA | Pseudomonas |
| 237 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefuroxime iv | NA | - | - | F49 | G49 | FALSE | NA | Pseudomonas |
| 238 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefuroxime oral | NA | - | - | B50 | C50 | FALSE | NA | Pseudomonas |
| 239 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Cefuroxime oral | NA | - | - | F50 | G50 | FALSE | NA | Pseudomonas |
| 240 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ertapenem | NA | - | - | B56 | C56 | FALSE | NA | Pseudomonas |
| 241 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ertapenem | NA | - | - | F56 | G56 | FALSE | NA | Pseudomonas |
| 242 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Imipenem | NA | 4 | 4 | B57 | C57 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 243 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Imipenem | 10 mcg | 20 | 20 | F57 | G57 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 244 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Meropenem | NA | 2 | 8 | B58 | C58 | FALSE | NA | Pseudomonas |
| 245 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Meropenem | 10 mcg | 24 | 18 | F58 | G58 | FALSE | NA | Pseudomonas |
| 246 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | P. aeruginosa | Pseudomonas spp. | NA | Meropenem-vaborbactam | NA | 8 | 8 | B59 | C59 | FALSE | [1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L. | Pseudomonas |
| 247 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | P. aeruginosa | Pseudomonas spp. | NA | Meropenem-vaborbactam | IP mcg | IP | IP | F59 | G59 | FALSE | NA | Pseudomonas |
| 248 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Aztreonam | NA | 16 | 16 | B64 | C64 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 249 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Aztreonam | 30 mcg | 18 | 18 | F64 | G64 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 250 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ciprofloxacin | NA | 0.5 | 0.5 | B69 | C69 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 251 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ciprofloxacin | 5 mcg | 26 | 26 | F69 | G69 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 252 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Levofloxacin | NA | 1 | 1 | B70 | C70 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 253 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Levofloxacin | 5 mcg | 22 | 22 | F70 | G70 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 254 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Moxifloxacin | NA | - | - | B71 | C71 | FALSE | NA | Pseudomonas |
| 255 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Moxifloxacin | NA | - | - | F71 | G71 | FALSE | NA | Pseudomonas |
| 256 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Nalidixic acid (screen) | NA | NA | NA | B72 | C72 | FALSE | NA | Pseudomonas |
| 257 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Nalidixic acid (screen) | NA | NA | NA | F72 | G72 | FALSE | NA | Pseudomonas |
| 258 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | B73 | C73 | FALSE | NA | Pseudomonas |
| 259 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | F73 | G73 | FALSE | NA | Pseudomonas |
| 260 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ofloxacin | NA | - | - | B74 | C74 | FALSE | NA | Pseudomonas |
| 261 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Ofloxacin | NA | - | - | F74 | G74 | FALSE | NA | Pseudomonas |
| 262 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Amikacin | NA | 8 | 16 | B79 | C79 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 263 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Amikacin | 30 mcg | 18 | 15 | F79 | G79 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 264 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Gentamicin | NA | 4 | 4 | B80 | C80 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 265 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Gentamicin | 10 mcg | 15 | 15 | F80 | G80 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 266 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Netilmicin | NA | 4 | 4 | B81 | C81 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 267 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Netilmicin | 10 mcg | 12 | 12 | F81 | G81 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 268 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Tobramycin | NA | 4 | 4 | B82 | C82 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 269 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Tobramycin | 10 mcg | 16 | 16 | F82 | G82 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Pseudomonas |
| 270 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Dalbavancin | NA | - | - | B87 | C87 | FALSE | NA | Pseudomonas |
| 271 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Dalbavancin | NA | - | - | F87 | G87 | FALSE | NA | Pseudomonas |
| 272 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Oritavancin | NA | - | - | B88 | C88 | FALSE | NA | Pseudomonas |
| 273 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Oritavancin | NA | - | - | F88 | G88 | FALSE | NA | Pseudomonas |
| 274 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Teicoplanin | NA | - | - | B89 | C89 | FALSE | NA | Pseudomonas |
| 275 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Teicoplanin | NA | - | - | F89 | G89 | FALSE | NA | Pseudomonas |
| 276 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Telavancin | NA | - | - | B90 | C90 | FALSE | NA | Pseudomonas |
| 277 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Telavancin | NA | - | - | F90 | G90 | FALSE | NA | Pseudomonas |
| 278 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Vancomycin | NA | - | - | B91 | C91 | FALSE | NA | Pseudomonas |
| 279 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Vancomycin | NA | - | - | F91 | G91 | FALSE | NA | Pseudomonas |
| 280 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Azithromycin | NA | - | - | B96 | C96 | FALSE | NA | Pseudomonas |
| 281 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Azithromycin | NA | - | - | F96 | G96 | FALSE | NA | Pseudomonas |
| 282 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Clarithromycin | NA | - | - | B97 | C97 | FALSE | NA | Pseudomonas |
| 283 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Clarithromycin | NA | - | - | F97 | G97 | FALSE | NA | Pseudomonas |
| 284 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Erythromycin | NA | - | - | B98 | C98 | FALSE | NA | Pseudomonas |
| 285 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Erythromycin | NA | - | - | F98 | G98 | FALSE | NA | Pseudomonas |
| 286 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Roxithromycin | NA | - | - | B99 | C99 | FALSE | NA | Pseudomonas |
| 287 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Roxithromycin | NA | - | - | F99 | G99 | FALSE | NA | Pseudomonas |
| 288 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Telithromycin | NA | - | - | B100 | C100 | FALSE | NA | Pseudomonas |
| 289 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Telithromycin | NA | - | - | F100 | G100 | FALSE | NA | Pseudomonas |
| 290 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Clindamycin | NA | - | - | B102 | C102 | FALSE | NA | Pseudomonas |
| 291 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Clindamycin | NA | - | - | F102 | G102 | FALSE | NA | Pseudomonas |
| 292 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Quinupristin-dalfopristin | NA | - | - | B103 | C103 | FALSE | NA | Pseudomonas |
| 293 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Quinupristin-dalfopristin | NA | - | - | F103 | G103 | FALSE | NA | Pseudomonas |
| 294 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Doxycycline | NA | - | - | B108 | C108 | FALSE | NA | Pseudomonas |
| 295 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Doxycycline | NA | - | - | F108 | G108 | FALSE | NA | Pseudomonas |
| 296 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Eravacycline | NA | - | - | B109 | C109 | FALSE | NA | Pseudomonas |
| 297 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Eravacycline | NA | - | - | F109 | G109 | FALSE | NA | Pseudomonas |
| 298 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Minocycline | NA | - | - | B110 | C110 | FALSE | NA | Pseudomonas |
| 299 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Minocycline | NA | - | - | F110 | G110 | FALSE | NA | Pseudomonas |
| 300 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Tetracycline | NA | - | - | B111 | C111 | FALSE | NA | Pseudomonas |
| 301 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Tetracycline | NA | - | - | F111 | G111 | FALSE | NA | Pseudomonas |
| 302 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Tigecycline | NA | - | - | B112 | C112 | FALSE | NA | Pseudomonas |
| 303 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Tigecycline | NA | - | - | F112 | G112 | FALSE | NA | Pseudomonas |
| 304 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Linezolid | NA | - | - | B117 | C117 | FALSE | NA | Pseudomonas |
| 305 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Linezolid | NA | - | - | F117 | G117 | FALSE | NA | Pseudomonas |
| 306 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Tedizolid | NA | - | - | B118 | C118 | FALSE | NA | Pseudomonas |
| 307 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Tedizolid | NA | - | - | F118 | G118 | FALSE | NA | Pseudomonas |
| 308 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Chloramphenicol | NA | - | - | B123 | C123 | FALSE | NA | Pseudomonas |
| 309 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Chloramphenicol | NA | - | - | F123 | G123 | FALSE | NA | Pseudomonas |
| 310 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Colistin | NA | 2 | 2 | B124 | C124 | FALSE | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Pseudomonas |
| 311 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Colistin | NA | Note | Note | F124 | G124 | FALSE | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Pseudomonas |
| 312 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Daptomycin | NA | - | - | B125 | C125 | FALSE | NA | Pseudomonas |
| 313 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Daptomycin | NA | - | - | F125 | G125 | FALSE | NA | Pseudomonas |
| 314 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Fosfomycin iv | NA | - | - | B126 | C126 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents. | Pseudomonas |
| 315 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Fosfomycin iv | NA | - | - | F126 | G126 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents. | Pseudomonas |
| 316 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Fosfomycin oral | NA | - | - | B127 | C127 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents. | Pseudomonas |
| 317 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Fosfomycin oral | NA | - | - | F127 | G127 | FALSE | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents. | Pseudomonas |
| 318 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Fusidic acid | NA | - | - | B128 | C128 | FALSE | NA | Pseudomonas |
| 319 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Fusidic acid | NA | - | - | F128 | G128 | FALSE | NA | Pseudomonas |
| 320 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Metronidazole | NA | - | - | B129 | C129 | FALSE | NA | Pseudomonas |
| 321 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Metronidazole | NA | - | - | F129 | G129 | FALSE | NA | Pseudomonas |
| 322 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | B130 | C130 | FALSE | NA | Pseudomonas |
| 323 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | F130 | G130 | FALSE | NA | Pseudomonas |
| 324 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | B131 | C131 | FALSE | NA | Pseudomonas |
| 325 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | F131 | G131 | FALSE | NA | Pseudomonas |
| 326 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Rifampicin | NA | - | - | B132 | C132 | FALSE | NA | Pseudomonas |
| 327 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Rifampicin | NA | - | - | F132 | G132 | FALSE | NA | Pseudomonas |
| 328 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Spectinomycin | NA | - | - | B133 | C133 | FALSE | NA | Pseudomonas |
| 329 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Spectinomycin | NA | - | - | F133 | G133 | FALSE | NA | Pseudomonas |
| 330 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | B134 | C134 | FALSE | NA | Pseudomonas |
| 331 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | F134 | G134 | FALSE | NA | Pseudomonas |
| 332 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Trimethoprim-sulfamethoxazole | NA | - | - | B135 | C135 | FALSE | NA | Pseudomonas |
| 333 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Pseudomonas spp. | Pseudomonas spp. | NA | Trimethoprim-sulfamethoxazole | NA | - | - | F135 | G135 | FALSE | NA | Pseudomonas |
| 334 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Stenotrophomonas maltophilia | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | NA | 4 | 4 | B10 | C10 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | S.maltophilia |
| 335 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Stenotrophomonas maltophilia | Stenotrophomonas maltophilia | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 16 | 16 | F10 | G10 | FALSE | [A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | S.maltophilia |
| 336 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Benzylpenicillin | NA | - | - | B10 | C10 | FALSE | NA | Acinetobacter |
| 337 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Benzylpenicillin | NA | - | - | F10 | G10 | FALSE | NA | Acinetobacter |
| 338 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ampicillin | NA | - | - | B11 | C11 | FALSE | NA | Acinetobacter |
| 339 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ampicillin | NA | - | - | F11 | G11 | FALSE | NA | Acinetobacter |
| 340 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ampicillin-sulbactam | NA | IE | IE | B12 | C12 | FALSE | NA | Acinetobacter |
| 341 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ampicillin-sulbactam | NA | IE | IE | F12 | G12 | FALSE | NA | Acinetobacter |
| 342 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Amoxicillin | NA | - | - | B13 | C13 | FALSE | NA | Acinetobacter |
| 343 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Amoxicillin | NA | - | - | F13 | G13 | FALSE | NA | Acinetobacter |
| 344 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Amoxicillin-clavulanic acid | NA | - | - | B14 | C14 | FALSE | NA | Acinetobacter |
| 345 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Amoxicillin-clavulanic acid | NA | - | - | F14 | G14 | FALSE | NA | Acinetobacter |
| 346 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Piperacillin | NA | IE | IE | B15 | C15 | FALSE | NA | Acinetobacter |
| 347 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Piperacillin | NA | IE | IE | F15 | G15 | FALSE | NA | Acinetobacter |
| 348 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Piperacillin-tazobactam | NA | IE | IE | B16 | C16 | FALSE | NA | Acinetobacter |
| 349 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Piperacillin-tazobactam | NA | IE | IE | F16 | G16 | FALSE | NA | Acinetobacter |
| 350 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ticarcillin | NA | IE | IE | B17 | C17 | FALSE | NA | Acinetobacter |
| 351 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ticarcillin | NA | IE | IE | F17 | G17 | FALSE | NA | Acinetobacter |
| 352 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | NA | IE | IE | B18 | C18 | FALSE | NA | Acinetobacter |
| 353 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ticarcillin-clavulanic acid | NA | IE | IE | F18 | G18 | FALSE | NA | Acinetobacter |
| 354 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Temocillin | NA | - | - | B19 | C19 | FALSE | NA | Acinetobacter |
| 355 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Temocillin | NA | - | - | F19 | G19 | FALSE | NA | Acinetobacter |
| 356 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Phenoxymethylpenicillin | NA | - | - | B21 | C21 | FALSE | NA | Acinetobacter |
| 357 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Phenoxymethylpenicillin | NA | - | - | F21 | G21 | FALSE | NA | Acinetobacter |
| 358 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Oxacillin | NA | - | - | B23 | C23 | FALSE | NA | Acinetobacter |
| 359 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Oxacillin | NA | - | - | F23 | G23 | FALSE | NA | Acinetobacter |
| 360 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cloxacillin | NA | - | - | B24 | C24 | FALSE | NA | Acinetobacter |
| 361 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cloxacillin | NA | - | - | F24 | G24 | FALSE | NA | Acinetobacter |
| 362 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Dicloxacillin | NA | - | - | B25 | C25 | FALSE | NA | Acinetobacter |
| 363 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Dicloxacillin | NA | - | - | F25 | G25 | FALSE | NA | Acinetobacter |
| 364 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Flucloxacillin | NA | - | - | B26 | C26 | FALSE | NA | Acinetobacter |
| 365 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Flucloxacillin | NA | - | - | F26 | G26 | FALSE | NA | Acinetobacter |
| 366 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B28 | C28 | FALSE | NA | Acinetobacter |
| 367 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | F28 | G28 | FALSE | NA | Acinetobacter |
| 368 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefaclor | NA | - | - | B33 | C33 | FALSE | NA | Acinetobacter |
| 369 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefaclor | NA | - | - | F33 | G33 | FALSE | NA | Acinetobacter |
| 370 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefadroxil | NA | - | - | B34 | C34 | FALSE | NA | Acinetobacter |
| 371 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefadroxil | NA | - | - | F34 | G34 | FALSE | NA | Acinetobacter |
| 372 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefalexin | NA | - | - | B35 | C35 | FALSE | NA | Acinetobacter |
| 373 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefalexin | NA | - | - | F35 | G35 | FALSE | NA | Acinetobacter |
| 374 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefazolin | NA | - | - | B36 | C36 | FALSE | NA | Acinetobacter |
| 375 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefazolin | NA | - | - | F36 | G36 | FALSE | NA | Acinetobacter |
| 376 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefepime | NA | - | - | B37 | C37 | FALSE | NA | Acinetobacter |
| 377 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefepime | NA | - | - | F37 | G37 | FALSE | NA | Acinetobacter |
| 378 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefixime | NA | - | - | B38 | C38 | FALSE | NA | Acinetobacter |
| 379 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefixime | NA | - | - | F38 | G38 | FALSE | NA | Acinetobacter |
| 380 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefotaxime | NA | - | - | B39 | C39 | FALSE | NA | Acinetobacter |
| 381 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefotaxime | NA | - | - | F39 | G39 | FALSE | NA | Acinetobacter |
| 382 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefoxitin | NA | - | - | B40 | C40 | FALSE | NA | Acinetobacter |
| 383 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefoxitin | NA | - | - | F40 | G40 | FALSE | NA | Acinetobacter |
| 384 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefpodoxime | NA | - | - | B41 | C41 | FALSE | NA | Acinetobacter |
| 385 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefpodoxime | NA | - | - | F41 | G41 | FALSE | NA | Acinetobacter |
| 386 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftaroline | NA | - | - | B42 | C42 | FALSE | NA | Acinetobacter |
| 387 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftaroline | NA | - | - | F42 | G42 | FALSE | NA | Acinetobacter |
| 388 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftazidime | NA | - | - | B43 | C43 | FALSE | NA | Acinetobacter |
| 389 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftazidime | NA | - | - | F43 | G43 | FALSE | NA | Acinetobacter |
| 390 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftazidime-avibactam | NA | - | - | B44 | C44 | FALSE | NA | Acinetobacter |
| 391 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftazidime-avibactam | NA | - | - | F44 | G44 | FALSE | NA | Acinetobacter |
| 392 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftibuten | NA | - | - | B45 | C45 | FALSE | NA | Acinetobacter |
| 393 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftibuten | NA | - | - | F45 | G45 | FALSE | NA | Acinetobacter |
| 394 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftobiprole | NA | - | - | B46 | C46 | FALSE | NA | Acinetobacter |
| 395 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftobiprole | NA | - | - | F46 | G46 | FALSE | NA | Acinetobacter |
| 396 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftolozane-tazobactam | NA | - | - | B47 | C47 | FALSE | NA | Acinetobacter |
| 397 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftolozane-tazobactam | NA | - | - | F47 | G47 | FALSE | NA | Acinetobacter |
| 398 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftriaxone | NA | - | - | B48 | C48 | FALSE | NA | Acinetobacter |
| 399 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ceftriaxone | NA | - | - | F48 | G48 | FALSE | NA | Acinetobacter |
| 400 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefuroxime iv | NA | - | - | B49 | C49 | FALSE | NA | Acinetobacter |
| 401 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefuroxime iv | NA | - | - | F49 | G49 | FALSE | NA | Acinetobacter |
| 402 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefuroxime oral | NA | - | - | B50 | C50 | FALSE | NA | Acinetobacter |
| 403 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Cefuroxime oral | NA | - | - | F50 | G50 | FALSE | NA | Acinetobacter |
| 404 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ertapenem | NA | - | - | B56 | C56 | FALSE | NA | Acinetobacter |
| 405 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ertapenem | NA | - | - | F56 | G56 | FALSE | NA | Acinetobacter |
| 406 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Imipenem | NA | 2 | 4 | B57 | C57 | FALSE | NA | Acinetobacter |
| 407 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Imipenem | 10 mcg | 24 | 21 | F57 | G57 | FALSE | NA | Acinetobacter |
| 408 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Meropenem | NA | 2 | 8 | B58 | C58 | FALSE | NA | Acinetobacter |
| 409 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Meropenem | 10 mcg | 21 | 15 | F58 | G58 | FALSE | NA | Acinetobacter |
| 410 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Meropenem-vaborbactam | NA | IE | IE | B59 | C59 | FALSE | NA | Acinetobacter |
| 411 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Meropenem-vaborbactam | NA | IE | IE | F59 | G59 | FALSE | NA | Acinetobacter |
| 412 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Aztreonam | NA | - | - | B64 | C64 | FALSE | NA | Acinetobacter |
| 413 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Aztreonam | NA | - | - | F64 | G64 | FALSE | NA | Acinetobacter |
| 414 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ciprofloxacin | NA | 0.06 | 1 | B69 | C69 | FALSE | NA | Acinetobacter |
| 415 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ciprofloxacin | 5 mcg | 50 | 21 | F69 | G69 | FALSE | NA | Acinetobacter |
| 416 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Levofloxacin | NA | 0.5 | 1 | B70 | C70 | FALSE | NA | Acinetobacter |
| 417 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Levofloxacin | 5 mcg | 23 | 20 | F70 | G70 | FALSE | NA | Acinetobacter |
| 418 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Moxifloxacin | NA | - | - | B71 | C71 | FALSE | NA | Acinetobacter |
| 419 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Moxifloxacin | NA | - | - | F71 | G71 | FALSE | NA | Acinetobacter |
| 420 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Nalidixic acid (screen) | NA | NA | NA | B72 | C72 | FALSE | NA | Acinetobacter |
| 421 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Nalidixic acid (screen) | NA | NA | NA | F72 | G72 | FALSE | NA | Acinetobacter |
| 422 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | B73 | C73 | FALSE | NA | Acinetobacter |
| 423 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | F73 | G73 | FALSE | NA | Acinetobacter |
| 424 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ofloxacin | NA | - | - | B74 | C74 | FALSE | NA | Acinetobacter |
| 425 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Ofloxacin | NA | - | - | F74 | G74 | FALSE | NA | Acinetobacter |
| 426 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Amikacin | NA | 8 | 16 | B79 | C79 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Acinetobacter |
| 427 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Amikacin | 30 mcg | 19 | 17 | F79 | G79 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Acinetobacter |
| 428 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Gentamicin | NA | 4 | 4 | B80 | C80 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Acinetobacter |
| 429 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Gentamicin | 10 mcg | 17 | 17 | F80 | G80 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Acinetobacter |
| 430 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Netilmicin | NA | 4 | 4 | B81 | C81 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Acinetobacter |
| 431 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Netilmicin | 10 mcg | 16 | 16 | F81 | G81 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Acinetobacter |
| 432 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Tobramycin | NA | 4 | 4 | B82 | C82 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Acinetobacter |
| 433 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Tobramycin | 10 mcg | 17 | 17 | F82 | G82 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Acinetobacter |
| 434 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Dalbavancin | NA | - | - | B87 | C87 | FALSE | NA | Acinetobacter |
| 435 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Dalbavancin | NA | - | - | F87 | G87 | FALSE | NA | Acinetobacter |
| 436 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Oritavancin | NA | - | - | B88 | C88 | FALSE | NA | Acinetobacter |
| 437 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Oritavancin | NA | - | - | F88 | G88 | FALSE | NA | Acinetobacter |
| 438 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Teicoplanin | NA | - | - | B89 | C89 | FALSE | NA | Acinetobacter |
| 439 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Teicoplanin | NA | - | - | F89 | G89 | FALSE | NA | Acinetobacter |
| 440 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Telavancin | NA | - | - | B90 | C90 | FALSE | NA | Acinetobacter |
| 441 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Telavancin | NA | - | - | F90 | G90 | FALSE | NA | Acinetobacter |
| 442 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Vancomycin | NA | - | - | B91 | C91 | FALSE | NA | Acinetobacter |
| 443 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Vancomycin | NA | - | - | F91 | G91 | FALSE | NA | Acinetobacter |
| 444 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Azithromycin | NA | - | - | B96 | C96 | FALSE | NA | Acinetobacter |
| 445 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Azithromycin | NA | - | - | F96 | G96 | FALSE | NA | Acinetobacter |
| 446 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Clarithromycin | NA | - | - | B97 | C97 | FALSE | NA | Acinetobacter |
| 447 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Clarithromycin | NA | - | - | F97 | G97 | FALSE | NA | Acinetobacter |
| 448 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Erythromycin | NA | - | - | B98 | C98 | FALSE | NA | Acinetobacter |
| 449 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Erythromycin | NA | - | - | F98 | G98 | FALSE | NA | Acinetobacter |
| 450 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Roxithromycin | NA | - | - | B99 | C99 | FALSE | NA | Acinetobacter |
| 451 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Roxithromycin | NA | - | - | F99 | G99 | FALSE | NA | Acinetobacter |
| 452 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Telithromycin | NA | - | - | B100 | C100 | FALSE | NA | Acinetobacter |
| 453 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Telithromycin | NA | - | - | F100 | G100 | FALSE | NA | Acinetobacter |
| 454 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Clindamycin | NA | - | - | B102 | C102 | FALSE | NA | Acinetobacter |
| 455 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Clindamycin | NA | - | - | F102 | G102 | FALSE | NA | Acinetobacter |
| 456 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Quinupristin-dalfopristin | NA | - | - | B103 | C103 | FALSE | NA | Acinetobacter |
| 457 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Quinupristin-dalfopristin | NA | - | - | F103 | G103 | FALSE | NA | Acinetobacter |
| 458 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Doxycycline | NA | - | - | B108 | C108 | FALSE | NA | Acinetobacter |
| 459 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Doxycycline | NA | - | - | F108 | G108 | FALSE | NA | Acinetobacter |
| 460 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Eravacycline | NA | IE | IE | B109 | C109 | FALSE | NA | Acinetobacter |
| 461 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Eravacycline | NA | IE | IE | F109 | G109 | FALSE | NA | Acinetobacter |
| 462 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Minocycline | NA | IE | IE | B110 | C110 | FALSE | NA | Acinetobacter |
| 463 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Minocycline | NA | IE | IE | F110 | G110 | FALSE | NA | Acinetobacter |
| 464 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Tetracycline | NA | - | - | B111 | C111 | FALSE | NA | Acinetobacter |
| 465 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Tetracycline | NA | - | - | F111 | G111 | FALSE | NA | Acinetobacter |
| 466 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Tigecycline | NA | IE | IE | B112 | C112 | FALSE | NA | Acinetobacter |
| 467 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Tigecycline | NA | IE | IE | F112 | G112 | FALSE | NA | Acinetobacter |
| 468 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Linezolid | NA | - | - | B117 | C117 | FALSE | NA | Acinetobacter |
| 469 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Linezolid | NA | - | - | F117 | G117 | FALSE | NA | Acinetobacter |
| 470 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Tedizolid | NA | - | - | B118 | C118 | FALSE | NA | Acinetobacter |
| 471 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Tedizolid | NA | - | - | F118 | G118 | FALSE | NA | Acinetobacter |
| 472 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Chloramphenicol | NA | - | - | B123 | C123 | FALSE | NA | Acinetobacter |
| 473 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Chloramphenicol | NA | - | - | F123 | G123 | FALSE | NA | Acinetobacter |
| 474 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Colistin | NA | 2 | 2 | B124 | C124 | FALSE | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Acinetobacter |
| 475 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Colistin | NA | Note | Note | F124 | G124 | FALSE | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive). | Acinetobacter |
| 476 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Daptomycin | NA | - | - | B125 | C125 | FALSE | NA | Acinetobacter |
| 477 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Daptomycin | NA | - | - | F125 | G125 | FALSE | NA | Acinetobacter |
| 478 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Fosfomycin iv | NA | - | - | B126 | C126 | FALSE | NA | Acinetobacter |
| 479 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Fosfomycin iv | NA | - | - | F126 | G126 | FALSE | NA | Acinetobacter |
| 480 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Fosfomycin oral | NA | - | - | B127 | C127 | FALSE | NA | Acinetobacter |
| 481 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Fosfomycin oral | NA | - | - | F127 | G127 | FALSE | NA | Acinetobacter |
| 482 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Fusidic acid | NA | - | - | B128 | C128 | FALSE | NA | Acinetobacter |
| 483 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Fusidic acid | NA | - | - | F128 | G128 | FALSE | NA | Acinetobacter |
| 484 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Metronidazole | NA | - | - | B129 | C129 | FALSE | NA | Acinetobacter |
| 485 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Metronidazole | NA | - | - | F129 | G129 | FALSE | NA | Acinetobacter |
| 486 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | B130 | C130 | FALSE | NA | Acinetobacter |
| 487 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | F130 | G130 | FALSE | NA | Acinetobacter |
| 488 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | B131 | C131 | FALSE | NA | Acinetobacter |
| 489 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | F131 | G131 | FALSE | NA | Acinetobacter |
| 490 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Rifampicin | NA | - | - | B132 | C132 | FALSE | NA | Acinetobacter |
| 491 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Rifampicin | NA | - | - | F132 | G132 | FALSE | NA | Acinetobacter |
| 492 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Spectinomycin | NA | - | - | B133 | C133 | FALSE | NA | Acinetobacter |
| 493 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Spectinomycin | NA | - | - | F133 | G133 | FALSE | NA | Acinetobacter |
| 494 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | B134 | C134 | FALSE | NA | Acinetobacter |
| 495 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | F134 | G134 | FALSE | NA | Acinetobacter |
| 496 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | NA | 2 | 4 | B135 | C135 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Acinetobacter |
| 497 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Acinetobacter spp. | Acinetobacter spp. | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 14 | 11 | F135 | G135 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Acinetobacter |
| 498 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Benzylpenicillin | NA | 0.125 | 0.125 | B10 | C10 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 499 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Benzylpenicillin | 1 unit | 26 | 26 | F10 | G10 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase. | Staphylococcus |
| 500 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. lugdunensis | Staphylococcus spp. | NA | Benzylpenicillin | NA | 0.125 | 0.125 | B11 | C11 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 501 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. lugdunensis | Staphylococcus spp. | NA | Benzylpenicillin | 1 unit | 26 | 26 | F11 | G11 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 502 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Benzylpenicillin | NA | - | - | B12 | C12 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | Staphylococcus |
| 503 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Benzylpenicillin | NA | Note | Note | F12 | G12 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | Staphylococcus |
| 504 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. saprophyticus | Staphylococcus spp. | NA | Ampicillin | NA | Note | Note | B13 | C13 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 505 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. saprophyticus | Staphylococcus spp. | NA | Ampicillin | 2 mcg | 18 | 18 | F13 | G13 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 506 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ampicillin-sulbactam | NA | Note | Note | B14 | C14 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 507 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ampicillin-sulbactam | NA | Note | Note | F14 | G14 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 508 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Amoxicillin | NA | Note | Note | B15 | C15 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 509 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Amoxicillin | NA | Note | Note | F15 | G15 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 510 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Amoxicillin-clavulanic acid | NA | Note | Note | B16 | C16 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 511 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Amoxicillin-clavulanic acid | NA | Note | Note | F16 | G16 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 512 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Piperacillin | NA | Note | Note | B17 | C17 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 513 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Piperacillin | NA | Note | Note | F17 | G17 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 514 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Piperacillin-tazobactam | NA | Note | Note | B18 | C18 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 515 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Piperacillin-tazobactam | NA | Note | Note | F18 | G18 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). | Staphylococcus |
| 516 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ticarcillin | NA | Note | Note | B19 | C19 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 517 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ticarcillin | NA | Note | Note | F19 | G19 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 518 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ticarcillin-clavulanic acid | NA | Note | Note | B20 | C20 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 519 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ticarcillin-clavulanic acid | NA | Note | Note | F20 | G20 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 520 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Temocillin | NA | - | - | B21 | C21 | FALSE | NA | Staphylococcus |
| 521 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Temocillin | NA | - | - | F21 | G21 | FALSE | NA | Staphylococcus |
| 522 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Phenoxymethylpenicillin | NA | Note | Note | B23 | C23 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 523 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Phenoxymethylpenicillin | NA | Note | Note | F23 | G23 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 524 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Phenoxymethylpenicillin | NA | - | - | B24 | C24 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | Staphylococcus |
| 525 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Phenoxymethylpenicillin | NA | Note | Note | F24 | G24 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 526 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Oxacillin | NA | Note | Note | B26 | C26 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 527 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Oxacillin | NA | Note | Note | F26 | G26 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L. | Staphylococcus |
| 528 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cloxacillin | NA | Note | Note | B27 | C27 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 529 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cloxacillin | NA | Note | Note | F27 | G27 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 530 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Dicloxacillin | NA | Note | Note | B28 | C28 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 531 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Dicloxacillin | NA | Note | Note | F28 | G28 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 532 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Flucloxacillin | NA | Note | Note | B29 | C29 | FALSE | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 533 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Flucloxacillin | NA | Note | Note | F29 | G29 | FALSE | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | Staphylococcus |
| 534 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B31 | C31 | FALSE | NA | Staphylococcus |
| 535 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | F31 | G31 | FALSE | NA | Staphylococcus |
| 536 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefaclor | NA | Note | Note | B36 | C36 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 537 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefaclor | NA | Note | Note | F36 | G36 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 538 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefadroxil | NA | Note | Note | B37 | C37 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 539 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefadroxil | NA | Note | Note | F37 | G37 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 540 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefalexin | NA | Note | Note | B38 | C38 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 541 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefalexin | NA | Note | Note | F38 | G38 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 542 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefazolin | NA | Note | Note | B39 | C39 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 543 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefazolin | NA | Note | Note | F39 | G39 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 544 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefepime | NA | Note | Note | B40 | C40 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 545 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefepime | NA | Note | Note | F40 | G40 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 546 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefixime | NA | - | - | B41 | C41 | FALSE | NA | Staphylococcus |
| 547 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefixime | NA | - | - | F41 | G41 | FALSE | NA | Staphylococcus |
| 548 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefotaxime | NA | Note | Note | B42 | C42 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 549 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefotaxime | NA | Note | Note | F42 | G42 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 550 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus and coagulase-negative staphylococci other than S. epidermidis | Staphylococcus spp. | NA | Cefoxitin (screen) | NA | Note | Note | B43 | C43 | FALSE | [2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | Staphylococcus |
| 551 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus and coagulase-negative staphylococci other than S. epidermidis | Staphylococcus spp. | NA | Cefoxitin (screen) | 30 mcg | 22 | 22 | F43 | G43 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 552 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. epidermidis | Staphylococcus spp. | NA | Cefoxitin (screen) | NA | Note | Note | B44 | C44 | FALSE | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test. | Staphylococcus |
| 553 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. epidermidis | Staphylococcus spp. | NA | Cefoxitin (screen) | 30 mcg | 25 | 25 | F44 | G44 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm. | Staphylococcus |
| 554 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. pseudintermedius | Staphylococcus spp. | NA | Cefoxitin (screen) | NA | NA | NA | B45 | C45 | FALSE | NA | Staphylococcus |
| 555 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. pseudintermedius | Staphylococcus spp. | NA | Cefoxitin (screen) | NA | Note | Note | F45 | G45 | FALSE | [C] Cefoxitin screen for methicillin resistance in S. pseudintermedius is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm to screen for methicillin resistance. | Staphylococcus |
| 556 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefpodoxime | NA | Note | Note | B46 | C46 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 557 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefpodoxime | NA | Note | Note | F46 | G46 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 558 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Ceftaroline (indications other than pneumonia) | NA | 1 | 2 | B47 | C47 | FALSE | [4] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 559 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Ceftaroline (indications other than pneumonia) | 5 mcg | 20 | 17 | F47 | G47 | FALSE | [D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 560 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Ceftaroline (pneumonia) | NA | 1 | 1 | B48 | C48 | FALSE | [4] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 561 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Ceftaroline (pneumonia) | 5 mcg | 20 | 20 | F48 | G48 | FALSE | [D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing. | Staphylococcus |
| 562 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftazidime | NA | - | - | B49 | C49 | FALSE | NA | Staphylococcus |
| 563 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftazidime | NA | - | - | F49 | G49 | FALSE | NA | Staphylococcus |
| 564 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftazidime-avibactam | NA | - | - | B50 | C50 | FALSE | NA | Staphylococcus |
| 565 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftazidime-avibactam | NA | - | - | F50 | G50 | FALSE | NA | Staphylococcus |
| 566 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftibuten | NA | - | - | B51 | C51 | FALSE | NA | Staphylococcus |
| 567 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftibuten | NA | - | - | F51 | G51 | FALSE | NA | Staphylococcus |
| 568 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Ceftobiprole | NA | 2 | 2 | B52 | C52 | FALSE | [6] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing. | Staphylococcus |
| 569 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Ceftobiprole | 5 mcg | 17 | 17 | F52 | G52 | FALSE | [F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing. | Staphylococcus |
| 570 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftolozane-tazobactam | NA | - | - | B53 | C53 | FALSE | NA | Staphylococcus |
| 571 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftolozane-tazobactam | NA | - | - | F53 | G53 | FALSE | NA | Staphylococcus |
| 572 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftriaxone | NA | Note | Note | B54 | C54 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 573 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ceftriaxone | NA | Note | Note | F54 | G54 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 574 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefuroxime iv | NA | Note | Note | B55 | C55 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 575 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefuroxime iv | NA | Note | Note | F55 | G55 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 576 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefuroxime oral | NA | Note | Note | B56 | C56 | FALSE | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 577 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Cefuroxime oral | NA | Note | Note | F56 | G56 | FALSE | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | Staphylococcus |
| 578 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ertapenem | NA | Note | Note | B62 | C62 | FALSE | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 579 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Ertapenem | NA | Note | Note | F62 | G62 | FALSE | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 580 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Imipenem | NA | Note | Note | B63 | C63 | FALSE | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 581 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Imipenem | NA | Note | Note | F63 | G63 | FALSE | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 582 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Meropenem | NA | Note | Note | B64 | C64 | FALSE | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 583 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Meropenem | NA | Note | Note | F64 | G64 | FALSE | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 584 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Meropenem-vaborbactam | NA | Note | Note | B65 | C65 | FALSE | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 585 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Meropenem-vaborbactam | NA | Note | Note | F65 | G65 | FALSE | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | Staphylococcus |
| 586 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Aztreonam | NA | - | - | B70 | C70 | FALSE | NA | Staphylococcus |
| 587 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Aztreonam | NA | - | - | F70 | G70 | FALSE | NA | Staphylococcus |
| 588 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Ciprofloxacin | NA | 1 | 1 | B75 | C75 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 589 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Ciprofloxacin | 5 mcg | 21 | 21 | F75 | G75 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 590 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Ciprofloxacin | NA | 1 | 1 | B76 | C76 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 591 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Ciprofloxacin | 5 mcg | 24 | 24 | F76 | G76 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 592 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Levofloxacin | NA | 1 | 1 | B77 | C77 | FALSE | NA | Staphylococcus |
| 593 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Levofloxacin | 5 mcg | 22 | 22 | F77 | G77 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | Staphylococcus |
| 594 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Levofloxacin | NA | 1 | 1 | B78 | C78 | FALSE | NA | Staphylococcus |
| 595 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Levofloxacin | 5 mcg | 24 | 24 | F78 | G78 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | Staphylococcus |
| 596 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Moxifloxacin | NA | 0.25 | 0.25 | B79 | C79 | FALSE | NA | Staphylococcus |
| 597 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Moxifloxacin | 5 mcg | 25 | 25 | F79 | G79 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | Staphylococcus |
| 598 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Moxifloxacin | NA | 0.25 | 0.25 | B80 | C80 | FALSE | NA | Staphylococcus |
| 599 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Moxifloxacin | 5 mcg | 28 | 28 | F80 | G80 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | Staphylococcus |
| 600 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Nalidixic acid (screen) | NA | NA | NA | B81 | C81 | FALSE | NA | Staphylococcus |
| 601 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Nalidixic acid (screen) | NA | NA | NA | F81 | G81 | FALSE | NA | Staphylococcus |
| 602 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Norfloxacin (screen) | NA | NA | NA | B82 | C82 | FALSE | NA | Staphylococcus |
| 603 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Norfloxacin (screen) | 10 mcg | 17 | Note | F82 | G82 | FALSE | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Staphylococcus |
| 604 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Ofloxacin | NA | 1 | 1 | B83 | C83 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 605 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Ofloxacin | 5 mcg | 20 | 20 | F83 | G83 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 606 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Ofloxacin | NA | 1 | 1 | B84 | C84 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 607 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Ofloxacin | 5 mcg | 24 | 24 | F84 | G84 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Staphylococcus |
| 608 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Amikacin | NA | 8 | 16 | B89 | C89 | FALSE | [1] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci. | Staphylococcus |
| 609 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Amikacin | 30 mcg | 18 | 16 | F89 | G89 | FALSE | [1] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci. | Staphylococcus |
| 610 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Amikacin | NA | 8 | 16 | B90 | C90 | FALSE | [1] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci. | Staphylococcus |
| 611 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Amikacin | 30 mcg | 22 | 19 | F90 | G90 | FALSE | [1] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci. | Staphylococcus |
| 612 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Gentamicin | NA | 1 | 1 | B91 | C91 | FALSE | NA | Staphylococcus |
| 613 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Gentamicin | 10 mcg | 18 | 18 | F91 | G91 | FALSE | NA | Staphylococcus |
| 614 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Gentamicin | NA | 1 | 1 | B92 | C92 | FALSE | NA | Staphylococcus |
| 615 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Gentamicin | 10 mcg | 22 | 22 | F92 | G92 | FALSE | NA | Staphylococcus |
| 616 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Netilmicin | NA | 1 | 1 | B93 | C93 | FALSE | NA | Staphylococcus |
| 617 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Netilmicin | 10 mcg | 18 | 18 | F93 | G93 | FALSE | NA | Staphylococcus |
| 618 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Netilmicin | NA | 1 | 1 | B94 | C94 | FALSE | NA | Staphylococcus |
| 619 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Netilmicin | 10 mcg | 22 | 22 | F94 | G94 | FALSE | NA | Staphylococcus |
| 620 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Tobramycin | NA | 1 | 1 | B95 | C95 | FALSE | NA | Staphylococcus |
| 621 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Tobramycin | 10 mcg | 18 | 18 | F95 | G95 | FALSE | NA | Staphylococcus |
| 622 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Tobramycin | NA | 1 | 1 | B96 | C96 | FALSE | NA | Staphylococcus |
| 623 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Tobramycin | 10 mcg | 22 | 22 | F96 | G96 | FALSE | NA | Staphylococcus |
| 624 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Dalbavancin | NA | 0.125 | 0.125 | B101 | C101 | FALSE | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 625 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Dalbavancin | NA | Note | Note | F101 | G101 | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 626 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Oritavancin | NA | 0.125 | 0.125 | B102 | C102 | FALSE | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 627 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Oritavancin | NA | Note | Note | F102 | G102 | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 628 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Teicoplanin | NA | 2 | 2 | B103 | C103 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 629 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Teicoplanin | NA | Note | Note | F103 | G103 | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 630 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Teicoplanin | NA | 4 | 4 | B104 | C104 | FALSE | NA | Staphylococcus |
| 631 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Teicoplanin | NA | Note | Note | F104 | G104 | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | Staphylococcus |
| 632 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | MRSA | Staphylococcus spp. | NA | Telavancin | NA | 0.125 | 0.125 | B105 | C105 | FALSE | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 633 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | MRSA | Staphylococcus spp. | NA | Telavancin | NA | Note | Note | F105 | G105 | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 634 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Vancomycin | NA | 2 | 2 | B106 | C106 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 635 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Vancomycin | NA | Note | Note | F106 | G106 | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 636 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Vancomycin | NA | 4 | 4 | B107 | C107 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 637 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Coagulase-negative staphylococci | Staphylococcus spp. | NA | Vancomycin | NA | Note | Note | F107 | G107 | FALSE | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 638 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Azithromycin | NA | 1 | 2 | B112 | C112 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 639 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Azithromycin | NA | Note | Note | F112 | G112 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 640 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Clarithromycin | NA | 1 | 2 | B113 | C113 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 641 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Clarithromycin | NA | Note | Note | F113 | G113 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 642 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Erythromycin | NA | 1 | 2 | B114 | C114 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 643 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Erythromycin | 15 mcg | 21 | 18 | F114 | G114 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 644 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Roxithromycin | NA | 1 | 2 | B115 | C115 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 645 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Roxithromycin | NA | Note | Note | F115 | G115 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Staphylococcus |
| 646 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Telithromycin | NA | IE | IE | B116 | C116 | FALSE | NA | Staphylococcus |
| 647 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Telithromycin | NA | IE | IE | F116 | G116 | FALSE | NA | Staphylococcus |
| 648 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Clindamycin | NA | 0.25 | 0.5 | B118 | C118 | FALSE | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". | Staphylococcus |
| 649 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Clindamycin | 2 mcg | 22 | 19 | F118 | G118 | FALSE | [B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". | Staphylococcus |
| 650 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Quinupristin-dalfopristin | NA | 1 | 2 | B119 | C119 | FALSE | NA | Staphylococcus |
| 651 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Quinupristin-dalfopristin | 15 mcg | 21 | 18 | F119 | G119 | FALSE | NA | Staphylococcus |
| 652 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Doxycycline | NA | 1 | 2 | B124 | C124 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 653 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Doxycycline | NA | Note | Note | F124 | G124 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 654 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. aureus | Staphylococcus spp. | NA | Eravacycline | NA | 0.25 | 0.25 | B125 | C125 | FALSE | NA | Staphylococcus |
| 655 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. aureus | Staphylococcus spp. | NA | Eravacycline | IP mcg | IP | IP | F125 | G125 | FALSE | NA | Staphylococcus |
| 656 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Minocycline | NA | 0.5 | 1 | B126 | C126 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 657 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Minocycline | 30 mcg | 23 | 20 | F126 | G126 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 658 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Tetracycline | NA | 1 | 2 | B127 | C127 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 659 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Tetracycline | 30 mcg | 22 | 19 | F127 | G127 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Staphylococcus |
| 660 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Tigecycline | NA | 0.5 | 0.5 | B128 | C128 | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 661 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Tigecycline | 15 mcg | 18 | 18 | F128 | G128 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 662 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Linezolid | NA | 4 | 4 | B133 | C133 | FALSE | NA | Staphylococcus |
| 663 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Linezolid | 10 mcg | 21 | 21 | F133 | G133 | FALSE | [A] Examine zone edges with transmitted light (plate held up to light). | Staphylococcus |
| 664 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Tedizolid | NA | 0.5 | 0.5 | B134 | C134 | FALSE | [1] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | Staphylococcus |
| 665 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Tedizolid | NA | Note | Note | F134 | G134 | FALSE | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | Staphylococcus |
| 666 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Chloramphenicol | NA | 8 | 8 | B139 | C139 | FALSE | NA | Staphylococcus |
| 667 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Chloramphenicol | 30 mcg | 18 | 18 | F139 | G139 | FALSE | NA | Staphylococcus |
| 668 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Colistin | NA | - | - | B140 | C140 | FALSE | NA | Staphylococcus |
| 669 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Colistin | NA | - | - | F140 | G140 | FALSE | NA | Staphylococcus |
| 670 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Daptomycin | NA | 1 | 1 | B141 | C141 | FALSE | [2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 671 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Daptomycin | NA | Note | Note | F141 | G141 | FALSE | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Staphylococcus |
| 672 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Fosfomycin iv | NA | 32 | 32 | B142 | C142 | FALSE | [3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | Staphylococcus |
| 673 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Fosfomycin iv | NA | Note | Note | F142 | G142 | FALSE | [A] Use an MIC method. | Staphylococcus |
| 674 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Fosfomycin oral | NA | - | - | B143 | C143 | FALSE | NA | Staphylococcus |
| 675 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Fosfomycin oral | NA | - | - | F143 | G143 | FALSE | NA | Staphylococcus |
| 676 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Fusidic acid | NA | 1 | 1 | B144 | C144 | FALSE | NA | Staphylococcus |
| 677 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Fusidic acid | 10 mcg | 24 | 24 | F144 | G144 | FALSE | NA | Staphylococcus |
| 678 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Metronidazole | NA | - | - | B145 | C145 | FALSE | NA | Staphylococcus |
| 679 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Metronidazole | NA | - | - | F145 | G145 | FALSE | NA | Staphylococcus |
| 680 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. saprophyticus | Staphylococcus spp. | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | B146 | C146 | FALSE | NA | Staphylococcus |
| 681 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. saprophyticus | Staphylococcus spp. | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 13 | 13 | F146 | G146 | FALSE | NA | Staphylococcus |
| 682 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. saprophyticus | Staphylococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | IE | IE | B147 | C147 | FALSE | NA | Staphylococcus |
| 683 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. saprophyticus | Staphylococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | IE | IE | F147 | G147 | FALSE | NA | Staphylococcus |
| 684 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Rifampicin | NA | 0.06 | 0.5 | B148 | C148 | FALSE | NA | Staphylococcus |
| 685 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Rifampicin | 5 mcg | 26 | 23 | F148 | G148 | FALSE | NA | Staphylococcus |
| 686 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Spectinomycin | NA | - | - | B149 | C149 | FALSE | NA | Staphylococcus |
| 687 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Spectinomycin | NA | - | - | F149 | G149 | FALSE | NA | Staphylococcus |
| 688 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | NA | 2 | 4 | B150 | C150 | FALSE | NA | Staphylococcus |
| 689 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | 17 | 14 | F150 | G150 | FALSE | NA | Staphylococcus |
| 690 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Trimethoprim-sulfamethoxazole | NA | 2 | 4 | B151 | C151 | FALSE | [4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Staphylococcus |
| 691 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Staphylococcus spp. | Staphylococcus spp. | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 17 | 14 | F151 | G151 | FALSE | [4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Staphylococcus |
| 692 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Benzylpenicillin | NA | - | - | B12 | C12 | FALSE | NA | Enterococcus |
| 693 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Benzylpenicillin | NA | - | - | F12 | G12 | FALSE | NA | Enterococcus |
| 694 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ampicillin | NA | 4 | 8 | B13 | C13 | FALSE | NA | Enterococcus |
| 695 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ampicillin | 2 mcg | 10 | 8 | F13 | G13 | FALSE | NA | Enterococcus |
| 696 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ampicillin-sulbactam | NA | 4 | 8 | B14 | C14 | FALSE | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 697 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ampicillin-sulbactam | NA | Note | Note | F14 | G14 | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 698 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Amoxicillin | NA | 4 | 8 | B15 | C15 | FALSE | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 699 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Amoxicillin | NA | Note | Note | F15 | G15 | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 700 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Amoxicillin-clavulanic acid | NA | 4 | 8 | B16 | C16 | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 701 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Amoxicillin-clavulanic acid | NA | Note | Note | F16 | G16 | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 702 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Piperacillin | NA | Note | Note | B17 | C17 | FALSE | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 703 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Piperacillin | NA | Note | Note | F17 | G17 | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 704 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Piperacillin-tazobactam | NA | Note | Note | B18 | C18 | FALSE | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 705 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Piperacillin-tazobactam | NA | Note | Note | F18 | G18 | FALSE | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin. | Enterococcus |
| 706 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ticarcillin | NA | - | - | B19 | C19 | FALSE | NA | Enterococcus |
| 707 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ticarcillin | NA | - | - | F19 | G19 | FALSE | NA | Enterococcus |
| 708 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ticarcillin-clavulanic acid | NA | - | - | B20 | C20 | FALSE | NA | Enterococcus |
| 709 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ticarcillin-clavulanic acid | NA | - | - | F20 | G20 | FALSE | NA | Enterococcus |
| 710 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Temocillin | NA | - | - | B21 | C21 | FALSE | NA | Enterococcus |
| 711 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Temocillin | NA | - | - | F21 | G21 | FALSE | NA | Enterococcus |
| 712 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Phenoxymethylpenicillin | NA | - | - | B23 | C23 | FALSE | NA | Enterococcus |
| 713 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Phenoxymethylpenicillin | NA | - | - | F23 | G23 | FALSE | NA | Enterococcus |
| 714 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Oxacillin | NA | - | - | B25 | C25 | FALSE | NA | Enterococcus |
| 715 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Oxacillin | NA | - | - | F25 | G25 | FALSE | NA | Enterococcus |
| 716 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cloxacillin | NA | - | - | B26 | C26 | FALSE | NA | Enterococcus |
| 717 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cloxacillin | NA | - | - | F26 | G26 | FALSE | NA | Enterococcus |
| 718 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Dicloxacillin | NA | - | - | B27 | C27 | FALSE | NA | Enterococcus |
| 719 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Dicloxacillin | NA | - | - | F27 | G27 | FALSE | NA | Enterococcus |
| 720 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Flucloxacillin | NA | - | - | B28 | C28 | FALSE | NA | Enterococcus |
| 721 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Flucloxacillin | NA | - | - | F28 | G28 | FALSE | NA | Enterococcus |
| 722 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B30 | C30 | FALSE | NA | Enterococcus |
| 723 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | F30 | G30 | FALSE | NA | Enterococcus |
| 724 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefaclor | NA | - | - | B35 | C35 | FALSE | NA | Enterococcus |
| 725 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefaclor | NA | - | - | F35 | G35 | FALSE | NA | Enterococcus |
| 726 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefadroxil | NA | - | - | B36 | C36 | FALSE | NA | Enterococcus |
| 727 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefadroxil | NA | - | - | F36 | G36 | FALSE | NA | Enterococcus |
| 728 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefalexin | NA | - | - | B37 | C37 | FALSE | NA | Enterococcus |
| 729 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefalexin | NA | - | - | F37 | G37 | FALSE | NA | Enterococcus |
| 730 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefazolin | NA | - | - | B38 | C38 | FALSE | NA | Enterococcus |
| 731 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefazolin | NA | - | - | F38 | G38 | FALSE | NA | Enterococcus |
| 732 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefepime | NA | - | - | B39 | C39 | FALSE | NA | Enterococcus |
| 733 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefepime | NA | - | - | F39 | G39 | FALSE | NA | Enterococcus |
| 734 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefixime | NA | - | - | B40 | C40 | FALSE | NA | Enterococcus |
| 735 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefixime | NA | - | - | F40 | G40 | FALSE | NA | Enterococcus |
| 736 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefotaxime | NA | - | - | B41 | C41 | FALSE | NA | Enterococcus |
| 737 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefotaxime | NA | - | - | F41 | G41 | FALSE | NA | Enterococcus |
| 738 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefoxitin | NA | - | - | B42 | C42 | FALSE | NA | Enterococcus |
| 739 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefoxitin | NA | - | - | F42 | G42 | FALSE | NA | Enterococcus |
| 740 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefpodoxime | NA | - | - | B43 | C43 | FALSE | NA | Enterococcus |
| 741 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefpodoxime | NA | - | - | F43 | G43 | FALSE | NA | Enterococcus |
| 742 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftaroline | NA | - | - | B44 | C44 | FALSE | NA | Enterococcus |
| 743 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftaroline | NA | - | - | F44 | G44 | FALSE | NA | Enterococcus |
| 744 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftazidime | NA | - | - | B45 | C45 | FALSE | NA | Enterococcus |
| 745 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftazidime | NA | - | - | F45 | G45 | FALSE | NA | Enterococcus |
| 746 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftazidime-avibactam | NA | - | - | B46 | C46 | FALSE | NA | Enterococcus |
| 747 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftazidime-avibactam | NA | - | - | F46 | G46 | FALSE | NA | Enterococcus |
| 748 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftibuten | NA | - | - | B47 | C47 | FALSE | NA | Enterococcus |
| 749 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftibuten | NA | - | - | F47 | G47 | FALSE | NA | Enterococcus |
| 750 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftobiprole | NA | - | - | B48 | C48 | FALSE | NA | Enterococcus |
| 751 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftobiprole | NA | - | - | F48 | G48 | FALSE | NA | Enterococcus |
| 752 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftolozane-tazobactam | NA | - | - | B49 | C49 | FALSE | NA | Enterococcus |
| 753 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftolozane-tazobactam | NA | - | - | F49 | G49 | FALSE | NA | Enterococcus |
| 754 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftriaxone | NA | - | - | B50 | C50 | FALSE | NA | Enterococcus |
| 755 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ceftriaxone | NA | - | - | F50 | G50 | FALSE | NA | Enterococcus |
| 756 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefuroxime iv | NA | - | - | B51 | C51 | FALSE | NA | Enterococcus |
| 757 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefuroxime iv | NA | - | - | F51 | G51 | FALSE | NA | Enterococcus |
| 758 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefuroxime oral | NA | - | - | B52 | C52 | FALSE | NA | Enterococcus |
| 759 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Cefuroxime oral | NA | - | - | F52 | G52 | FALSE | NA | Enterococcus |
| 760 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ertapenem | NA | - | - | B58 | C58 | FALSE | NA | Enterococcus |
| 761 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ertapenem | NA | - | - | F58 | G58 | FALSE | NA | Enterococcus |
| 762 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Imipenem | NA | 4 | 8 | B59 | C59 | FALSE | NA | Enterococcus |
| 763 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Imipenem | 10 mcg | 21 | 18 | F59 | G59 | FALSE | NA | Enterococcus |
| 764 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Meropenem | NA | - | - | B60 | C60 | FALSE | NA | Enterococcus |
| 765 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Meropenem | NA | - | - | F60 | G60 | FALSE | NA | Enterococcus |
| 766 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Meropenem-vaborbactam | NA | - | - | B61 | C61 | FALSE | NA | Enterococcus |
| 767 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Meropenem-vaborbactam | NA | - | - | F61 | G61 | FALSE | NA | Enterococcus |
| 768 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Aztreonam | NA | - | - | B66 | C66 | FALSE | NA | Enterococcus |
| 769 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Aztreonam | NA | - | - | F66 | G66 | FALSE | NA | Enterococcus |
| 770 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ciprofloxacin (uncomplicated UTI only) | NA | 4 | 4 | B71 | C71 | FALSE | NA | Enterococcus |
| 771 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ciprofloxacin (uncomplicated UTI only) | 5 mcg | 15 | 15 | F71 | G71 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | Enterococcus |
| 772 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Levofloxacin (uncomplicated UTI only) | NA | 4 | 4 | B72 | C72 | FALSE | NA | Enterococcus |
| 773 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Levofloxacin (uncomplicated UTI only) | 5 mcg | 15 | 15 | F72 | G72 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | Enterococcus |
| 774 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Moxifloxacin | NA | - | - | B73 | C73 | FALSE | NA | Enterococcus |
| 775 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Moxifloxacin | NA | - | - | F73 | G73 | FALSE | NA | Enterococcus |
| 776 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Nalidixic acid (screen) | NA | NA | NA | B74 | C74 | FALSE | NA | Enterococcus |
| 777 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Nalidixic acid (screen) | NA | NA | NA | F74 | G74 | FALSE | NA | Enterococcus |
| 778 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Norfloxacin (screen) | NA | NA | NA | B75 | C75 | FALSE | NA | Enterococcus |
| 779 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Norfloxacin (screen) | 10 mcg | 12 | 12 | F75 | G75 | FALSE | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. | Enterococcus |
| 780 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Ofloxacin | NA | - | - | B76 | C76 | FALSE | NA | Enterococcus |
| 781 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Ofloxacin | NA | - | - | F76 | G76 | FALSE | NA | Enterococcus |
| 782 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Amikacin | NA | Note | Note | B81 | C81 | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 783 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Amikacin | NA | Note | Note | F81 | G81 | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 784 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Gentamicin (test for high-level aminoglycoside resistance) | NA | Note | Note | B82 | C82 | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 785 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Gentamicin (test for high-level aminoglycoside resistance) | 30 mcg | Note | Note | F82 | G82 | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 786 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Netilmicin | NA | Note | Note | B83 | C83 | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 787 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Netilmicin | NA | Note | Note | F83 | G83 | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 788 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Streptomycin (test for high-level streptomycin resistance) | NA | Note | Note | B84 | C84 | FALSE | [3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 789 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Streptomycin (test for high-level streptomycin resistance) | 300 mcg | Note | Note | F84 | G84 | FALSE | [B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 790 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Tobramycin | NA | Note | Note | B85 | C85 | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 791 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Tobramycin | NA | Note | Note | F85 | G85 | FALSE | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides. | Enterococcus |
| 792 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Dalbavancin | NA | IE | IE | B90 | C90 | FALSE | NA | Enterococcus |
| 793 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Dalbavancin | NA | IE | IE | F90 | G90 | FALSE | NA | Enterococcus |
| 794 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Oritavancin | NA | IE | IE | B91 | C91 | FALSE | NA | Enterococcus |
| 795 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Oritavancin | NA | IE | IE | F91 | G91 | FALSE | NA | Enterococcus |
| 796 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Teicoplanin | NA | 2 | 2 | B92 | C92 | FALSE | NA | Enterococcus |
| 797 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Teicoplanin | 30 mcg | 16 | 16 | F92 | G92 | FALSE | NA | Enterococcus |
| 798 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Telavancin | NA | IE | IE | B93 | C93 | FALSE | NA | Enterococcus |
| 799 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Telavancin | NA | IE | IE | F93 | G93 | FALSE | NA | Enterococcus |
| 800 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Vancomycin | NA | 4 | 4 | B94 | C94 | FALSE | NA | Enterococcus |
| 801 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Vancomycin | 5 mcg | 12 | 12 | F94 | G94 | FALSE | [A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation. | Enterococcus |
| 802 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Azithromycin | NA | - | - | B99 | C99 | FALSE | NA | Enterococcus |
| 803 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Azithromycin | NA | - | - | F99 | G99 | FALSE | NA | Enterococcus |
| 804 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Clarithromycin | NA | - | - | B100 | C100 | FALSE | NA | Enterococcus |
| 805 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Clarithromycin | NA | - | - | F100 | G100 | FALSE | NA | Enterococcus |
| 806 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Erythromycin | NA | - | - | B101 | C101 | FALSE | NA | Enterococcus |
| 807 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Erythromycin | NA | - | - | F101 | G101 | FALSE | NA | Enterococcus |
| 808 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Roxithromycin | NA | - | - | B102 | C102 | FALSE | NA | Enterococcus |
| 809 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Roxithromycin | NA | - | - | F102 | G102 | FALSE | NA | Enterococcus |
| 810 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Telithromycin | NA | - | - | B103 | C103 | FALSE | NA | Enterococcus |
| 811 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Telithromycin | NA | - | - | F103 | G103 | FALSE | NA | Enterococcus |
| 812 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Clindamycin | NA | - | - | B105 | C105 | FALSE | NA | Enterococcus |
| 813 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Clindamycin | NA | - | - | F105 | G105 | FALSE | NA | Enterococcus |
| 814 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. faecium | Enterococcus spp. | NA | Quinupristin-dalfopristin | NA | 1 | 4 | B106 | C106 | FALSE | NA | Enterococcus |
| 815 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. faecium | Enterococcus spp. | NA | Quinupristin-dalfopristin | 15 mcg | 22 | 20 | F106 | G106 | FALSE | NA | Enterococcus |
| 816 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Doxycycline | NA | - | - | B111 | C111 | FALSE | NA | Enterococcus |
| 817 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Doxycycline | NA | - | - | F111 | G111 | FALSE | NA | Enterococcus |
| 818 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Eravacycline | NA | 0.125 | 0.125 | B112 | C112 | FALSE | NA | Enterococcus |
| 819 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Eravacycline | IP mcg | IP | IP | F112 | G112 | FALSE | NA | Enterococcus |
| 820 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Minocycline | NA | - | - | B113 | C113 | FALSE | NA | Enterococcus |
| 821 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Minocycline | NA | - | - | F113 | G113 | FALSE | NA | Enterococcus |
| 822 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Tetracycline | NA | - | - | B114 | C114 | FALSE | NA | Enterococcus |
| 823 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Tetracycline | NA | - | - | F114 | G114 | FALSE | NA | Enterococcus |
| 824 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Tigecycline | NA | 0.25 | 0.25 | B115 | C115 | FALSE | [2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Enterococcus |
| 825 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Tigecycline | 15 mcg | 18 | 18 | F115 | G115 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Enterococcus |
| 826 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Linezolid | NA | 4 | 4 | B120 | C120 | FALSE | NA | Enterococcus |
| 827 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Linezolid | 10 mcg | 19 | 19 | F120 | G120 | FALSE | NA | Enterococcus |
| 828 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Tedizolid | NA | IE | IE | B121 | C121 | FALSE | NA | Enterococcus |
| 829 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Tedizolid | NA | IE | IE | F121 | G121 | FALSE | NA | Enterococcus |
| 830 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Chloramphenicol | NA | - | - | B126 | C126 | FALSE | NA | Enterococcus |
| 831 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Chloramphenicol | NA | - | - | F126 | G126 | FALSE | NA | Enterococcus |
| 832 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Colistin | NA | - | - | B127 | C127 | FALSE | NA | Enterococcus |
| 833 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Colistin | NA | - | - | F127 | G127 | FALSE | NA | Enterococcus |
| 834 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Daptomycin | NA | IE | IE | B128 | C128 | FALSE | [1] For more information, see http://www.eucast.org/guidance_documents/. | Enterococcus |
| 835 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Daptomycin | NA | IE | IE | F128 | G128 | FALSE | [1] For more information, see http://www.eucast.org/guidance_documents/. | Enterococcus |
| 836 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Fosfomycin iv | NA | - | - | B129 | C129 | FALSE | NA | Enterococcus |
| 837 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Fosfomycin iv | NA | - | - | F129 | G129 | FALSE | NA | Enterococcus |
| 838 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Fosfomycin oral | NA | - | - | B130 | C130 | FALSE | NA | Enterococcus |
| 839 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Fosfomycin oral | NA | - | - | F130 | G130 | FALSE | NA | Enterococcus |
| 840 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Fusidic acid | NA | - | - | B131 | C131 | FALSE | NA | Enterococcus |
| 841 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Fusidic acid | NA | - | - | F131 | G131 | FALSE | NA | Enterococcus |
| 842 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Metronidazole | NA | - | - | B132 | C132 | FALSE | NA | Enterococcus |
| 843 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Metronidazole | NA | - | - | F132 | G132 | FALSE | NA | Enterococcus |
| 844 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | E. faecalis | Enterococcus spp. | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | B133 | C133 | FALSE | NA | Enterococcus |
| 845 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | E. faecalis | Enterococcus spp. | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 15 | 15 | F133 | G133 | FALSE | NA | Enterococcus |
| 846 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | IE | IE | B134 | C134 | FALSE | NA | Enterococcus |
| 847 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Nitroxoline (uncomplicated UTI only) | NA | IE | IE | F134 | G134 | FALSE | NA | Enterococcus |
| 848 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Rifampicin | NA | - | - | B135 | C135 | FALSE | NA | Enterococcus |
| 849 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Rifampicin | NA | - | - | F135 | G135 | FALSE | NA | Enterococcus |
| 850 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Spectinomycin | NA | - | - | B136 | C136 | FALSE | NA | Enterococcus |
| 851 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Spectinomycin | NA | - | - | F136 | G136 | FALSE | NA | Enterococcus |
| 852 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | NA | Note | Note | B137 | C137 | FALSE | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 853 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | Note | Note | F137 | G137 | FALSE | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | Enterococcus |
| 854 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Enterococcus spp. | Enterococcus spp. | NA | Trimethoprim-sulfamethoxazole | NA | Note | Note | B138 | C138 | FALSE | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterococcus |
| 855 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Enterococcus spp. | Enterococcus spp. | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | Note | Note | F138 | G138 | FALSE | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Enterococcus |
| 856 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Benzylpenicillin | NA | 0.25 | 0.25 | B8 | C8 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 857 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Benzylpenicillin | 1 unit | 18 | 18 | F8 | G8 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 858 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ampicillin | NA | Note | Note | B9 | C9 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 859 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ampicillin | NA | Note | Note | F9 | G9 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 860 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ampicillin-sulbactam | NA | Note | Note | B10 | C10 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 861 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ampicillin-sulbactam | NA | Note | Note | F10 | G10 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 862 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Amoxicillin | NA | Note | Note | B11 | C11 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 863 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Amoxicillin | NA | Note | Note | F11 | G11 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 864 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Amoxicillin-clavulanic acid | NA | Note | Note | B12 | C12 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 865 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Amoxicillin-clavulanic acid | NA | Note | Note | F12 | G12 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 866 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Piperacillin | NA | Note | Note | B13 | C13 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 867 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Piperacillin | NA | Note | Note | F13 | G13 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 868 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Piperacillin-tazobactam | NA | Note | Note | B14 | C14 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 869 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Piperacillin-tazobactam | NA | Note | Note | F14 | G14 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 870 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ticarcillin | NA | - | - | B15 | C15 | FALSE | NA | Streptococcus A,B,C,G |
| 871 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ticarcillin | NA | - | - | F15 | G15 | FALSE | NA | Streptococcus A,B,C,G |
| 872 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ticarcillin-clavulanic acid | NA | - | - | B16 | C16 | FALSE | NA | Streptococcus A,B,C,G |
| 873 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ticarcillin-clavulanic acid | NA | - | - | F16 | G16 | FALSE | NA | Streptococcus A,B,C,G |
| 874 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Temocillin | NA | - | - | B17 | C17 | FALSE | NA | Streptococcus A,B,C,G |
| 875 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Temocillin | NA | - | - | F17 | G17 | FALSE | NA | Streptococcus A,B,C,G |
| 876 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Phenoxymethylpenicillin | NA | Note | Note | B19 | C19 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 877 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Phenoxymethylpenicillin | NA | Note | Note | F19 | G19 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 878 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Oxacillin | NA | NA | NA | B21 | C21 | FALSE | NA | Streptococcus A,B,C,G |
| 879 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Oxacillin | NA | NA | NA | F21 | G21 | FALSE | NA | Streptococcus A,B,C,G |
| 880 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Cloxacillin | NA | Note | Note | B22 | C22 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 881 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Cloxacillin | NA | Note | Note | F22 | G22 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 882 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Dicloxacillin | NA | Note | Note | B23 | C23 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 883 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Dicloxacillin | NA | Note | Note | F23 | G23 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 884 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Flucloxacillin | NA | Note | Note | B24 | C24 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 885 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, C and G | Streptococcus groups A, B, C and G | NA | Flucloxacillin | NA | Note | Note | F24 | G24 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | Streptococcus A,B,C,G |
| 886 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B26 | C26 | FALSE | NA | Streptococcus A,B,C,G |
| 887 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | F26 | G26 | FALSE | NA | Streptococcus A,B,C,G |
| 888 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefaclor | NA | Note | Note | B31 | C31 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 889 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefaclor | NA | Note | Note | F31 | G31 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 890 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefadroxil | NA | Note | Note | B32 | C32 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 891 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefadroxil | NA | Note | Note | F32 | G32 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 892 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefalexin | NA | Note | Note | B33 | C33 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 893 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefalexin | NA | Note | Note | F33 | G33 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 894 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefazolin | NA | Note | Note | B34 | C34 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 895 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefazolin | NA | Note | Note | F34 | G34 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 896 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefepime | NA | Note | Note | B35 | C35 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 897 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefepime | NA | Note | Note | F35 | G35 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 898 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefixime | NA | - | - | B36 | C36 | FALSE | NA | Streptococcus A,B,C,G |
| 899 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefixime | NA | - | - | F36 | G36 | FALSE | NA | Streptococcus A,B,C,G |
| 900 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefotaxime | NA | Note | Note | B37 | C37 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 901 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefotaxime | NA | Note | Note | F37 | G37 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 902 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefoxitin | NA | NA | NA | B38 | C38 | FALSE | NA | Streptococcus A,B,C,G |
| 903 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefoxitin | NA | NA | NA | F38 | G38 | FALSE | NA | Streptococcus A,B,C,G |
| 904 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefpodoxime | NA | Note | Note | B39 | C39 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 905 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefpodoxime | NA | Note | Note | F39 | G39 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 906 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftaroline | NA | Note | Note | B40 | C40 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 907 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftaroline | NA | Note | Note | F40 | G40 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 908 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftazidime | NA | - | - | B41 | C41 | FALSE | NA | Streptococcus A,B,C,G |
| 909 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftazidime | NA | - | - | F41 | G41 | FALSE | NA | Streptococcus A,B,C,G |
| 910 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftazidime-avibactam | NA | - | - | B42 | C42 | FALSE | NA | Streptococcus A,B,C,G |
| 911 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftazidime-avibactam | NA | - | - | F42 | G42 | FALSE | NA | Streptococcus A,B,C,G |
| 912 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftibuten | NA | Note | Note | B43 | C43 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 913 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftibuten | NA | Note | Note | F43 | G43 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 914 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftobiprole | NA | IE | IE | B44 | C44 | FALSE | NA | Streptococcus A,B,C,G |
| 915 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftobiprole | NA | IE | IE | F44 | G44 | FALSE | NA | Streptococcus A,B,C,G |
| 916 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftolozane-tazobactam | NA | IE | IE | B45 | C45 | FALSE | NA | Streptococcus A,B,C,G |
| 917 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftolozane-tazobactam | NA | IE | IE | F45 | G45 | FALSE | NA | Streptococcus A,B,C,G |
| 918 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftriaxone | NA | Note | Note | B46 | C46 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 919 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ceftriaxone | NA | Note | Note | F46 | G46 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 920 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefuroxime iv | NA | Note | Note | B47 | C47 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 921 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefuroxime iv | NA | Note | Note | F47 | G47 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 922 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefuroxime oral | NA | Note | Note | B48 | C48 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 923 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Cefuroxime oral | NA | Note | Note | F48 | G48 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 924 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ertapenem | NA | Note | Note | B54 | C54 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 925 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ertapenem | NA | Note | Note | F54 | G54 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 926 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Imipenem | NA | Note | Note | B55 | C55 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 927 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Imipenem | NA | Note | Note | F55 | G55 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 928 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Meropenem | NA | Note | Note | B56 | C56 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 929 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Meropenem | NA | Note | Note | F56 | G56 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | Streptococcus A,B,C,G |
| 930 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Meropenem-vaborbactam | NA | Note | Note | B57 | C57 | FALSE | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 931 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Meropenem-vaborbactam | NA | Note | Note | F57 | G57 | FALSE | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit. | Streptococcus A,B,C,G |
| 932 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Aztreonam | NA | - | - | B62 | C62 | FALSE | NA | Streptococcus A,B,C,G |
| 933 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Aztreonam | NA | - | - | F62 | G62 | FALSE | NA | Streptococcus A,B,C,G |
| 934 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ciprofloxacin | NA | - | - | B67 | C67 | FALSE | NA | Streptococcus A,B,C,G |
| 935 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ciprofloxacin | NA | - | - | F67 | G67 | FALSE | NA | Streptococcus A,B,C,G |
| 936 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Levofloxacin | NA | 2 | 2 | B68 | C68 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Streptococcus A,B,C,G |
| 937 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Levofloxacin | 5 mcg | 17 | 17 | F68 | G68 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | Streptococcus A,B,C,G |
| 938 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Moxifloxacin | NA | 0.5 | 0.5 | B69 | C69 | FALSE | NA | Streptococcus A,B,C,G |
| 939 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Moxifloxacin | 5 mcg | 19 | 19 | F69 | G69 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | Streptococcus A,B,C,G |
| 940 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Nalidixic acid (screen) | NA | NA | NA | B70 | C70 | FALSE | NA | Streptococcus A,B,C,G |
| 941 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Nalidixic acid (screen) | NA | NA | NA | F70 | G70 | FALSE | NA | Streptococcus A,B,C,G |
| 942 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Norfloxacin (screen) | NA | NA | NA | B71 | C71 | FALSE | NA | Streptococcus A,B,C,G |
| 943 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Norfloxacin (screen) | 10 mcg | 12 | Note | F71 | G71 | FALSE | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Streptococcus A,B,C,G |
| 944 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ofloxacin | NA | - | - | B72 | C72 | FALSE | NA | Streptococcus A,B,C,G |
| 945 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Ofloxacin | NA | - | - | F72 | G72 | FALSE | NA | Streptococcus A,B,C,G |
| 946 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Amikacin | NA | - | - | B77 | C77 | FALSE | NA | Streptococcus A,B,C,G |
| 947 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Amikacin | NA | - | - | F77 | G77 | FALSE | NA | Streptococcus A,B,C,G |
| 948 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Gentamicin | NA | - | - | B78 | C78 | FALSE | NA | Streptococcus A,B,C,G |
| 949 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Gentamicin | NA | - | - | F78 | G78 | FALSE | NA | Streptococcus A,B,C,G |
| 950 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Netilmicin | NA | - | - | B79 | C79 | FALSE | NA | Streptococcus A,B,C,G |
| 951 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Netilmicin | NA | - | - | F79 | G79 | FALSE | NA | Streptococcus A,B,C,G |
| 952 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Tobramycin | NA | - | - | B80 | C80 | FALSE | NA | Streptococcus A,B,C,G |
| 953 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Tobramycin | NA | - | - | F80 | G80 | FALSE | NA | Streptococcus A,B,C,G |
| 954 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Dalbavancin | NA | 0.125 | 0.125 | B85 | C85 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 955 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Dalbavancin | NA | Note | Note | F85 | G85 | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 956 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Oritavancin | NA | 0.25 | 0.25 | B86 | C86 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 957 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Oritavancin | NA | Note | Note | F86 | G86 | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 958 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Teicoplanin | NA | 2 | 2 | B87 | C87 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 959 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Teicoplanin | 30 mcg | 15 | 15 | F87 | G87 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 960 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Telavancin | NA | IE | IE | B88 | C88 | FALSE | NA | Streptococcus A,B,C,G |
| 961 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Telavancin | NA | IE | IE | F88 | G88 | FALSE | NA | Streptococcus A,B,C,G |
| 962 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Vancomycin | NA | 2 | 2 | B89 | C89 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 963 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Vancomycin | 5 mcg | 13 | 13 | F89 | G89 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 964 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Azithromycin | NA | 0.25 | 0.5 | B94 | C94 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 965 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Azithromycin | NA | Note | Note | F94 | G94 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 966 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Clarithromycin | NA | 0.25 | 0.5 | B95 | C95 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 967 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Clarithromycin | NA | Note | Note | F95 | G95 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 968 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Erythromycin | NA | 0.25 | 0.5 | B96 | C96 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 969 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Erythromycin | 15 mcg | 21 | 18 | F96 | G96 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 970 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Roxithromycin | NA | 0.5 | 1 | B97 | C97 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 971 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Roxithromycin | NA | Note | Note | F97 | G97 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | Streptococcus A,B,C,G |
| 972 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Telithromycin | NA | 0.25 | 0.5 | B98 | C98 | FALSE | NA | Streptococcus A,B,C,G |
| 973 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Telithromycin | 15 mcg | 20 | 17 | F98 | G98 | FALSE | NA | Streptococcus A,B,C,G |
| 974 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Clindamycin | NA | 0.5 | 0.5 | B100 | C100 | FALSE | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known. | Streptococcus A,B,C,G |
| 975 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Clindamycin | 2 mcg | 17 | 17 | F100 | G100 | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: "Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known. | Streptococcus A,B,C,G |
| 976 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Quinupristin-dalfopristin | NA | - | - | B101 | C101 | FALSE | NA | Streptococcus A,B,C,G |
| 977 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Quinupristin-dalfopristin | NA | - | - | F101 | G101 | FALSE | NA | Streptococcus A,B,C,G |
| 978 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Doxycycline | NA | 1 | 2 | B106 | C106 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 979 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Doxycycline | NA | Note | Note | F106 | G106 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 980 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Eravacycline | NA | IE | IE | B107 | C107 | FALSE | NA | Streptococcus A,B,C,G |
| 981 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Eravacycline | NA | IE | IE | F107 | G107 | FALSE | NA | Streptococcus A,B,C,G |
| 982 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Minocycline | NA | 0.5 | 1 | B108 | C108 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 983 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Minocycline | 30 mcg | 23 | 20 | F108 | G108 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 984 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Tetracycline | NA | 1 | 2 | B109 | C109 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 985 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Tetracycline | 30 mcg | 23 | 20 | F109 | G109 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | Streptococcus A,B,C,G |
| 986 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Tigecycline | NA | 0.125 | 0.125 | B110 | C110 | FALSE | [3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 987 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Tigecycline | 15 mcg | 19 | 19 | F110 | G110 | FALSE | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 988 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Linezolid | NA | 2 | 4 | B115 | C115 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 989 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Linezolid | 10 mcg | 19 | 16 | F115 | G115 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 990 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Tedizolid | NA | 0.5 | 0.5 | B116 | C116 | FALSE | [2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 991 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Tedizolid | NA | Note | Note | F116 | G116 | FALSE | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 992 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Chloramphenicol | NA | 8 | 8 | B121 | C121 | FALSE | NA | Streptococcus A,B,C,G |
| 993 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Chloramphenicol | 30 mcg | 19 | 19 | F121 | G121 | FALSE | NA | Streptococcus A,B,C,G |
| 994 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Colistin | NA | - | - | B122 | C122 | FALSE | NA | Streptococcus A,B,C,G |
| 995 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Colistin | NA | - | - | F122 | G122 | FALSE | NA | Streptococcus A,B,C,G |
| 996 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Daptomycin | NA | 1 | 1 | B123 | C123 | FALSE | [2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 997 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Daptomycin | NA | Note | Note | F123 | G123 | FALSE | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Streptococcus A,B,C,G |
| 998 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Fosfomycin iv | NA | - | - | B124 | C124 | FALSE | NA | Streptococcus A,B,C,G |
| 999 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Fosfomycin iv | NA | - | - | F124 | G124 | FALSE | NA | Streptococcus A,B,C,G |
| 1000 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Fosfomycin oral | NA | - | - | B125 | C125 | FALSE | NA | Streptococcus A,B,C,G |
| 1001 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Fosfomycin oral | NA | - | - | F125 | G125 | FALSE | NA | Streptococcus A,B,C,G |
| 1002 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Fusidic acid | NA | IE | IE | B126 | C126 | FALSE | NA | Streptococcus A,B,C,G |
| 1003 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Fusidic acid | NA | IE | IE | F126 | G126 | FALSE | NA | Streptococcus A,B,C,G |
| 1004 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Metronidazole | NA | - | - | B127 | C127 | FALSE | NA | Streptococcus A,B,C,G |
| 1005 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Metronidazole | NA | - | - | F127 | G127 | FALSE | NA | Streptococcus A,B,C,G |
| 1006 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. agalactiae (group B streptococci) | Streptococcus groups A, B, C and G | NA | Nitrofurantoin (uncomplicated UTI only) | NA | 64 | 64 | B128 | C128 | FALSE | NA | Streptococcus A,B,C,G |
| 1007 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. agalactiae (group B streptococci) | Streptococcus groups A, B, C and G | NA | Nitrofurantoin (uncomplicated UTI only) | 100 mcg | 15 | 15 | F128 | G128 | FALSE | NA | Streptococcus A,B,C,G |
| 1008 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | B129 | C129 | FALSE | NA | Streptococcus A,B,C,G |
| 1009 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | F129 | G129 | FALSE | NA | Streptococcus A,B,C,G |
| 1010 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Rifampicin | NA | 0.06 | 0.5 | B130 | C130 | FALSE | NA | Streptococcus A,B,C,G |
| 1011 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Rifampicin | 5 mcg | 21 | 15 | F130 | G130 | FALSE | NA | Streptococcus A,B,C,G |
| 1012 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Spectinomycin | NA | - | - | B131 | C131 | FALSE | NA | Streptococcus A,B,C,G |
| 1013 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Spectinomycin | NA | - | - | F131 | G131 | FALSE | NA | Streptococcus A,B,C,G |
| 1014 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. agalactiae (group B streptococci) | Streptococcus groups A, B, C and G | NA | Trimethoprim (uncomplicated UTI only) | NA | 2 | 2 | B132 | C132 | FALSE | NA | Streptococcus A,B,C,G |
| 1015 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. agalactiae (group B streptococci) | Streptococcus groups A, B, C and G | NA | Trimethoprim (uncomplicated UTI only) | 5 mcg | IP | IP | F132 | G132 | FALSE | NA | Streptococcus A,B,C,G |
| 1016 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Trimethoprim-sulfamethoxazole | NA | 1 | 2 | B133 | C133 | FALSE | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Streptococcus A,B,C,G |
| 1017 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus groups A, B, C and G | Streptococcus groups A, B, C and G | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 18 | 15 | F133 | G133 | FALSE | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | Streptococcus A,B,C,G |
| 1018 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Benzylpenicillin (indications other than meningitis) | NA | 0.06 | 2 | B8 | C8 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages. | S.pneumoniae |
| 1019 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Benzylpenicillin (indications other than meningitis) | NA | Note | Note | F8 | G8 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages. | S.pneumoniae |
| 1020 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Benzylpenicillin (meningitis) | NA | 0.06 | 0.06 | B9 | C9 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1021 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Benzylpenicillin (meningitis) | NA | Note | Note | F9 | G9 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1022 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ampicillin | NA | 0.5 | 2 | B10 | C10 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1023 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ampicillin | 2 mcg | 22 | 16 | F10 | G10 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1024 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ampicillin-sulbactam | NA | Note | Note | B11 | C11 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1025 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ampicillin-sulbactam | NA | Note | Note | F11 | G11 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1026 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amoxicillin iv | NA | Note | Note | B12 | C12 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1027 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amoxicillin iv | NA | Note | Note | F12 | G12 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1028 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amoxicillin oral | NA | 0.5 | 1 | B13 | C13 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1029 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amoxicillin oral | NA | Note | Note | F13 | G13 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | S.pneumoniae |
| 1030 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid iv | NA | Note | Note | B14 | C14 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1031 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid iv | NA | Note | Note | F14 | G14 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1032 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid oral | NA | 0.5 | 1 | B15 | C15 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | S.pneumoniae |
| 1033 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amoxicillin-clavulanic acid oral | NA | Note | Note | F15 | G15 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | S.pneumoniae |
| 1034 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Piperacillin | NA | Note | Note | B16 | C16 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1035 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Piperacillin | NA | Note | Note | F16 | G16 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1036 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Piperacillin-tazobactam | NA | Note | Note | B17 | C17 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1037 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Piperacillin-tazobactam | NA | Note | Note | F17 | G17 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | S.pneumoniae |
| 1038 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ticarcillin | NA | - | - | B18 | C18 | FALSE | NA | S.pneumoniae |
| 1039 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ticarcillin | NA | - | - | F18 | G18 | FALSE | NA | S.pneumoniae |
| 1040 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ticarcillin-clavulanic acid | NA | - | - | B19 | C19 | FALSE | NA | S.pneumoniae |
| 1041 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ticarcillin-clavulanic acid | NA | - | - | F19 | G19 | FALSE | NA | S.pneumoniae |
| 1042 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Temocillin | NA | - | - | B20 | C20 | FALSE | NA | S.pneumoniae |
| 1043 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Temocillin | NA | - | - | F20 | G20 | FALSE | NA | S.pneumoniae |
| 1044 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Phenoxymethylpenicillin | NA | Note | Note | B22 | C22 | FALSE | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1045 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Phenoxymethylpenicillin | NA | Note | Note | F22 | G22 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1046 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Oxacillin (screen) | NA | NA | NA | B24 | C24 | FALSE | NA | S.pneumoniae |
| 1047 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Oxacillin (screen) | 1 mcg | 20 | Note | F24 | G24 | FALSE | [D] For interpretation of the oxacillin disk screen, see flow chart below. | S.pneumoniae |
| 1048 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cloxacillin | NA | - | - | B25 | C25 | FALSE | NA | S.pneumoniae |
| 1049 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cloxacillin | NA | - | - | F25 | G25 | FALSE | NA | S.pneumoniae |
| 1050 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Dicloxacillin | NA | - | - | B26 | C26 | FALSE | NA | S.pneumoniae |
| 1051 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Dicloxacillin | NA | - | - | F26 | G26 | FALSE | NA | S.pneumoniae |
| 1052 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Flucloxacillin | NA | - | - | B27 | C27 | FALSE | NA | S.pneumoniae |
| 1053 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Flucloxacillin | NA | - | - | F27 | G27 | FALSE | NA | S.pneumoniae |
| 1054 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B29 | C29 | FALSE | NA | S.pneumoniae |
| 1055 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | F29 | G29 | FALSE | NA | S.pneumoniae |
| 1056 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefaclor | NA | 0.03 | 0.5 | B34 | C34 | FALSE | NA | S.pneumoniae |
| 1057 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefaclor | 30 mcg | 50 | 28 | F34 | G34 | FALSE | NA | S.pneumoniae |
| 1058 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefadroxil | NA | - | - | B35 | C35 | FALSE | NA | S.pneumoniae |
| 1059 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefadroxil | NA | - | - | F35 | G35 | FALSE | NA | S.pneumoniae |
| 1060 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefalexin | NA | - | - | B36 | C36 | FALSE | NA | S.pneumoniae |
| 1061 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefalexin | NA | - | - | F36 | G36 | FALSE | NA | S.pneumoniae |
| 1062 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefazolin | NA | - | - | B37 | C37 | FALSE | NA | S.pneumoniae |
| 1063 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefazolin | NA | - | - | F37 | G37 | FALSE | NA | S.pneumoniae |
| 1064 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefepime | NA | 1 | 2 | B38 | C38 | FALSE | NA | S.pneumoniae |
| 1065 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefepime | NA | Note | Note | F38 | G38 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1066 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefixime | NA | - | - | B39 | C39 | FALSE | NA | S.pneumoniae |
| 1067 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefixime | NA | - | - | F39 | G39 | FALSE | NA | S.pneumoniae |
| 1068 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefotaxime | NA | 0.5 | 2 | B40 | C40 | FALSE | NA | S.pneumoniae |
| 1069 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefotaxime | NA | Note | Note | F40 | G40 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1070 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefoxitin | NA | NA | NA | B41 | C41 | FALSE | NA | S.pneumoniae |
| 1071 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefoxitin | NA | NA | NA | F41 | G41 | FALSE | NA | S.pneumoniae |
| 1072 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefpodoxime | NA | 0.25 | 0.5 | B42 | C42 | FALSE | NA | S.pneumoniae |
| 1073 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefpodoxime | NA | Note | Note | F42 | G42 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1074 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftaroline | NA | 0.25 | 0.25 | B43 | C43 | FALSE | NA | S.pneumoniae |
| 1075 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftaroline | NA | Note | Note | F43 | G43 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1076 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftazidime | NA | - | - | B44 | C44 | FALSE | NA | S.pneumoniae |
| 1077 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftazidime | NA | - | - | F44 | G44 | FALSE | NA | S.pneumoniae |
| 1078 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftazidime-avibactam | NA | - | - | B45 | C45 | FALSE | NA | S.pneumoniae |
| 1079 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftazidime-avibactam | NA | - | - | F45 | G45 | FALSE | NA | S.pneumoniae |
| 1080 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftibuten | NA | - | - | B46 | C46 | FALSE | NA | S.pneumoniae |
| 1081 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftibuten | NA | - | - | F46 | G46 | FALSE | NA | S.pneumoniae |
| 1082 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftobiprole | NA | 0.5 | 0.5 | B47 | C47 | FALSE | NA | S.pneumoniae |
| 1083 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftobiprole | NA | Note | Note | F47 | G47 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1084 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftolozane-tazobactam | NA | - | - | B48 | C48 | FALSE | NA | S.pneumoniae |
| 1085 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftolozane-tazobactam | NA | - | - | F48 | G48 | FALSE | NA | S.pneumoniae |
| 1086 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftriaxone | NA | 0.5 | 2 | B49 | C49 | FALSE | NA | S.pneumoniae |
| 1087 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ceftriaxone | NA | Note | Note | F49 | G49 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1088 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefuroxime iv | NA | 0.5 | 1 | B50 | C50 | FALSE | NA | S.pneumoniae |
| 1089 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefuroxime iv | NA | Note | Note | F50 | G50 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1090 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefuroxime oral | NA | 0.25 | 0.5 | B51 | C51 | FALSE | NA | S.pneumoniae |
| 1091 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Cefuroxime oral | NA | Note | Note | F51 | G51 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | S.pneumoniae |
| 1092 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ertapenem | NA | 0.5 | 0.5 | B57 | C57 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 1093 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ertapenem | NA | Note | Note | F57 | G57 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 1094 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Imipenem | NA | 2 | 2 | B58 | C58 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 1095 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Imipenem | NA | Note | Note | F58 | G58 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 1096 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Meropenem (indications other than meningitis) | NA | 2 | 2 | B59 | C59 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 1097 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Meropenem (indications other than meningitis) | NA | Note | Note | F59 | G59 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | S.pneumoniae |
| 1098 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Meropenem(meningitis) | NA | 0.25 | 0.25 | B60 | C60 | FALSE | [3] Meropenem is the only carbapenem used for meningitis. | S.pneumoniae |
| 1099 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Meropenem(meningitis) | NA | Note | Note | F60 | G60 | FALSE | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC. | [3] Meropenem is the only carbapenem used for meningitis. | S.pneumoniae |
| 1100 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Meropenem-vaborbactam | NA | IE | IE | B61 | C61 | FALSE | NA | S.pneumoniae |
| 1101 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Meropenem-vaborbactam | NA | IE | IE | F61 | G61 | FALSE | NA | S.pneumoniae |
| 1102 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Aztreonam | NA | - | - | B66 | C66 | FALSE | NA | S.pneumoniae |
| 1103 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Aztreonam | NA | - | - | F66 | G66 | FALSE | NA | S.pneumoniae |
| 1104 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ciprofloxacin | NA | - | - | B71 | C71 | FALSE | NA | S.pneumoniae |
| 1105 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ciprofloxacin | NA | - | - | F71 | G71 | FALSE | NA | S.pneumoniae |
| 1106 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Levofloxacin | NA | 2 | 2 | B72 | C72 | FALSE | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | S.pneumoniae |
| 1107 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Levofloxacin | 5 mcg | 16 | 16 | F72 | G72 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | S.pneumoniae |
| 1108 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Moxifloxacin | NA | 0.5 | 0.5 | B73 | C73 | FALSE | NA | S.pneumoniae |
| 1109 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Moxifloxacin | 5 mcg | 22 | 22 | F73 | G73 | FALSE | [A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | S.pneumoniae |
| 1110 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Nalidixic acid (screen) | NA | NA | NA | B74 | C74 | FALSE | NA | S.pneumoniae |
| 1111 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Nalidixic acid (screen) | NA | NA | NA | F74 | G74 | FALSE | NA | S.pneumoniae |
| 1112 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Norfloxacin (screen) | NA | NA | NA | B75 | C75 | FALSE | NA | S.pneumoniae |
| 1113 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Norfloxacin (screen) | 10 mcg | 10 | Note | F75 | G75 | FALSE | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | S.pneumoniae |
| 1114 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ofloxacin | NA | - | - | B76 | C76 | FALSE | NA | S.pneumoniae |
| 1115 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Ofloxacin | NA | - | - | F76 | G76 | FALSE | NA | S.pneumoniae |
| 1116 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amikacin | NA | - | - | B81 | C81 | FALSE | NA | S.pneumoniae |
| 1117 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Amikacin | NA | - | - | F81 | G81 | FALSE | NA | S.pneumoniae |
| 1118 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Gentamicin | NA | - | - | B82 | C82 | FALSE | NA | S.pneumoniae |
| 1119 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Gentamicin | NA | - | - | F82 | G82 | FALSE | NA | S.pneumoniae |
| 1120 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Netilmicin | NA | - | - | B83 | C83 | FALSE | NA | S.pneumoniae |
| 1121 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Netilmicin | NA | - | - | F83 | G83 | FALSE | NA | S.pneumoniae |
| 1122 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Tobramycin | NA | - | - | B84 | C84 | FALSE | NA | S.pneumoniae |
| 1123 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Tobramycin | NA | - | - | F84 | G84 | FALSE | NA | S.pneumoniae |
| 1124 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Dalbavancin | NA | IE | IE | B89 | C89 | FALSE | NA | S.pneumoniae |
| 1125 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Dalbavancin | NA | IE | IE | F89 | G89 | FALSE | NA | S.pneumoniae |
| 1126 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Oritavancin | NA | IE | IE | B90 | C90 | FALSE | NA | S.pneumoniae |
| 1127 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Oritavancin | NA | IE | IE | F90 | G90 | FALSE | NA | S.pneumoniae |
| 1128 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Teicoplanin | NA | 2 | 2 | B91 | C91 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 1129 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Teicoplanin | 30 mcg | 17 | 17 | F91 | G91 | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 1130 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Telavancin | NA | IE | IE | B92 | C92 | FALSE | NA | S.pneumoniae |
| 1131 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Telavancin | NA | IE | IE | F92 | G92 | FALSE | NA | S.pneumoniae |
| 1132 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Vancomycin | NA | 2 | 2 | B93 | C93 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 1133 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Vancomycin | 5 mcg | 16 | 16 | F93 | G93 | FALSE | [A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | S.pneumoniae |
| 1134 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Azithromycin | NA | 0.25 | 0.5 | B98 | C98 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1135 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Azithromycin | NA | Note | Note | F98 | G98 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1136 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Clarithromycin | NA | 0.25 | 0.5 | B99 | C99 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1137 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Clarithromycin | NA | Note | Note | F99 | G99 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1138 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Erythromycin | NA | 0.25 | 0.5 | B100 | C100 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1139 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Erythromycin | 15 mcg | 22 | 19 | F100 | G100 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1140 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Roxithromycin | NA | 0.5 | 1 | B101 | C101 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1141 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Roxithromycin | NA | Note | Note | F101 | G101 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | S.pneumoniae |
| 1142 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Telithromycin | NA | 0.25 | 0.5 | B102 | C102 | FALSE | NA | S.pneumoniae |
| 1143 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Telithromycin | 15 mcg | 23 | 20 | F102 | G102 | FALSE | NA | S.pneumoniae |
| 1144 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Clindamycin | NA | 0.5 | 0.5 | B104 | C104 | FALSE | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | S.pneumoniae |
| 1145 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Clindamycin | 2 mcg | 19 | 19 | F104 | G104 | FALSE | [B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | S.pneumoniae |
| 1146 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Quinupristin-dalfopristin | NA | - | - | B105 | C105 | FALSE | NA | S.pneumoniae |
| 1147 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Quinupristin-dalfopristin | NA | - | - | F105 | G105 | FALSE | NA | S.pneumoniae |
| 1148 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Doxycycline | NA | 1 | 2 | B110 | C110 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1149 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Doxycycline | NA | Note | Note | F110 | G110 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1150 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Eravacycline | NA | IE | IE | B111 | C111 | FALSE | NA | S.pneumoniae |
| 1151 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Eravacycline | NA | IE | IE | F111 | G111 | FALSE | NA | S.pneumoniae |
| 1152 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Minocycline | NA | 0.5 | 1 | B112 | C112 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1153 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Minocycline | 30 mcg | 24 | 21 | F112 | G112 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1154 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Tetracycline | NA | 1 | 2 | B113 | C113 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1155 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Tetracycline | 30 mcg | 25 | 22 | F113 | G113 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | S.pneumoniae |
| 1156 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Tigecycline | NA | IE | IE | B114 | C114 | FALSE | NA | S.pneumoniae |
| 1157 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Tigecycline | NA | IE | IE | F114 | G114 | FALSE | NA | S.pneumoniae |
| 1158 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Linezolid | NA | 2 | 4 | B119 | C119 | FALSE | NA | S.pneumoniae |
| 1159 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Linezolid | 10 mcg | 22 | 19 | F119 | G119 | FALSE | NA | S.pneumoniae |
| 1160 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Tedizolid | NA | IE | IE | B120 | C120 | FALSE | NA | S.pneumoniae |
| 1161 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Tedizolid | NA | IE | IE | F120 | G120 | FALSE | NA | S.pneumoniae |
| 1162 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Chloramphenicol | NA | 8 | 8 | B125 | C125 | FALSE | NA | S.pneumoniae |
| 1163 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Chloramphenicol | 30 mcg | 21 | 21 | F125 | G125 | FALSE | NA | S.pneumoniae |
| 1164 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Colistin | NA | - | - | B126 | C126 | FALSE | NA | S.pneumoniae |
| 1165 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Colistin | NA | - | - | F126 | G126 | FALSE | NA | S.pneumoniae |
| 1166 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Daptomycin | NA | IE | IE | B127 | C127 | FALSE | NA | S.pneumoniae |
| 1167 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Daptomycin | NA | IE | IE | F127 | G127 | FALSE | NA | S.pneumoniae |
| 1168 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Fosfomycin iv | NA | IE | IE | B128 | C128 | FALSE | NA | S.pneumoniae |
| 1169 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Fosfomycin iv | NA | IE | IE | F128 | G128 | FALSE | NA | S.pneumoniae |
| 1170 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Fosfomycin oral | NA | - | - | B129 | C129 | FALSE | NA | S.pneumoniae |
| 1171 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Fosfomycin oral | NA | - | - | F129 | G129 | FALSE | NA | S.pneumoniae |
| 1172 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Fusidic acid | NA | - | - | B130 | C130 | FALSE | NA | S.pneumoniae |
| 1173 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Fusidic acid | NA | - | - | F130 | G130 | FALSE | NA | S.pneumoniae |
| 1174 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Metronidazole | NA | - | - | B131 | C131 | FALSE | NA | S.pneumoniae |
| 1175 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Metronidazole | NA | - | - | F131 | G131 | FALSE | NA | S.pneumoniae |
| 1176 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | B132 | C132 | FALSE | NA | S.pneumoniae |
| 1177 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | F132 | G132 | FALSE | NA | S.pneumoniae |
| 1178 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | B133 | C133 | FALSE | NA | S.pneumoniae |
| 1179 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | F133 | G133 | FALSE | NA | S.pneumoniae |
| 1180 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Rifampicin | NA | 0.06 | 0.5 | B134 | C134 | FALSE | NA | S.pneumoniae |
| 1181 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Rifampicin | 5 mcg | 22 | 17 | F134 | G134 | FALSE | NA | S.pneumoniae |
| 1182 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Spectinomycin | NA | - | - | B135 | C135 | FALSE | NA | S.pneumoniae |
| 1183 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Spectinomycin | NA | - | - | F135 | G135 | FALSE | NA | S.pneumoniae |
| 1184 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | B136 | C136 | FALSE | NA | S.pneumoniae |
| 1185 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | F136 | G136 | FALSE | NA | S.pneumoniae |
| 1186 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Trimethoprim-sulfamethoxazole | NA | 1 | 2 | B137 | C137 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.pneumoniae |
| 1187 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Streptococcus pneumoniae | Streptococcus pneumoniae | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 13 | 10 | F137 | G137 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | S.pneumoniae |
| 1188 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Benzylpenicillin | NA | 0.25 | 2 | B12 | C12 | FALSE | NA | Viridans group streptococci |
| 1189 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Benzylpenicillin | 1 unit | 18 | 12 | F12 | G12 | FALSE | NA | Viridans group streptococci |
| 1190 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Benzylpenicillin (screen) | NA | NA | NA | B13 | C13 | FALSE | NA | Viridans group streptococci |
| 1191 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Benzylpenicillin (screen) | 1 unit | 18 | Note | F13 | G13 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | Viridans group streptococci |
| 1192 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ampicillin | NA | 0.5 | 2 | B14 | C14 | FALSE | NA | Viridans group streptococci |
| 1193 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ampicillin | 2 mcg | 21 | 15 | F14 | G14 | FALSE | NA | Viridans group streptococci |
| 1194 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ampicillin-sulbactam | NA | Note | Note | B15 | C15 | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1195 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ampicillin-sulbactam | NA | Note | Note | F15 | G15 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1196 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Amoxicillin | NA | 0.5 | 2 | B16 | C16 | FALSE | NA | Viridans group streptococci |
| 1197 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Amoxicillin | NA | Note | Note | F16 | G16 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1198 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Amoxicillin-clavulanic acid | NA | Note | Note | B17 | C17 | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1199 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Amoxicillin-clavulanic acid | NA | Note | Note | F17 | G17 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1200 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Piperacillin | NA | Note | Note | B18 | C18 | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1201 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Piperacillin | NA | Note | Note | F18 | G18 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1202 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Piperacillin-tazobactam | NA | Note | Note | B19 | C19 | FALSE | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1203 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Piperacillin-tazobactam | NA | Note | Note | F19 | G19 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin. | Viridans group streptococci |
| 1204 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ticarcillin | NA | IE | IE | B20 | C20 | FALSE | NA | Viridans group streptococci |
| 1205 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ticarcillin | NA | IE | IE | F20 | G20 | FALSE | NA | Viridans group streptococci |
| 1206 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ticarcillin-clavulanic acid | NA | IE | IE | B21 | C21 | FALSE | NA | Viridans group streptococci |
| 1207 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ticarcillin-clavulanic acid | NA | IE | IE | F21 | G21 | FALSE | NA | Viridans group streptococci |
| 1208 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Temocillin | NA | - | - | B22 | C22 | FALSE | NA | Viridans group streptococci |
| 1209 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Temocillin | NA | - | - | F22 | G22 | FALSE | NA | Viridans group streptococci |
| 1210 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Phenoxymethylpenicillin | NA | IE | IE | B24 | C24 | FALSE | NA | Viridans group streptococci |
| 1211 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Phenoxymethylpenicillin | NA | IE | IE | F24 | G24 | FALSE | NA | Viridans group streptococci |
| 1212 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Oxacillin | NA | - | - | B26 | C26 | FALSE | NA | Viridans group streptococci |
| 1213 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Oxacillin | NA | - | - | F26 | G26 | FALSE | NA | Viridans group streptococci |
| 1214 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cloxacillin | NA | - | - | B27 | C27 | FALSE | NA | Viridans group streptococci |
| 1215 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cloxacillin | NA | - | - | F27 | G27 | FALSE | NA | Viridans group streptococci |
| 1216 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Dicloxacillin | NA | - | - | B28 | C28 | FALSE | NA | Viridans group streptococci |
| 1217 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Dicloxacillin | NA | - | - | F28 | G28 | FALSE | NA | Viridans group streptococci |
| 1218 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Flucloxacillin | NA | - | - | B29 | C29 | FALSE | NA | Viridans group streptococci |
| 1219 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Flucloxacillin | NA | - | - | F29 | G29 | FALSE | NA | Viridans group streptococci |
| 1220 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B31 | C31 | FALSE | NA | Viridans group streptococci |
| 1221 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | F31 | G31 | FALSE | NA | Viridans group streptococci |
| 1222 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefaclor | NA | - | - | B36 | C36 | FALSE | NA | Viridans group streptococci |
| 1223 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefaclor | NA | - | - | F36 | G36 | FALSE | NA | Viridans group streptococci |
| 1224 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefadroxil | NA | - | - | B37 | C37 | FALSE | NA | Viridans group streptococci |
| 1225 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefadroxil | NA | - | - | F37 | G37 | FALSE | NA | Viridans group streptococci |
| 1226 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefalexin | NA | - | - | B38 | C38 | FALSE | NA | Viridans group streptococci |
| 1227 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefalexin | NA | - | - | F38 | G38 | FALSE | NA | Viridans group streptococci |
| 1228 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefazolin | NA | 0.5 | 0.5 | B39 | C39 | FALSE | NA | Viridans group streptococci |
| 1229 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefazolin | 30 mcg | IP | IP | F39 | G39 | FALSE | NA | Viridans group streptococci |
| 1230 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefepime | NA | 0.5 | 0.5 | B40 | C40 | FALSE | NA | Viridans group streptococci |
| 1231 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefepime | 30 mcg | 25 | 25 | F40 | G40 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1232 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefixime | NA | - | - | B41 | C41 | FALSE | NA | Viridans group streptococci |
| 1233 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefixime | NA | - | - | F41 | G41 | FALSE | NA | Viridans group streptococci |
| 1234 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefotaxime | NA | 0.5 | 0.5 | B42 | C42 | FALSE | NA | Viridans group streptococci |
| 1235 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefotaxime | 5 mcg | 23 | 23 | F42 | G42 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1236 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefoxitin | NA | NA | NA | B43 | C43 | FALSE | NA | Viridans group streptococci |
| 1237 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefoxitin | NA | NA | NA | F43 | G43 | FALSE | NA | Viridans group streptococci |
| 1238 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefpodoxime | NA | - | - | B44 | C44 | FALSE | NA | Viridans group streptococci |
| 1239 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefpodoxime | NA | - | - | F44 | G44 | FALSE | NA | Viridans group streptococci |
| 1240 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftaroline | NA | - | - | B45 | C45 | FALSE | NA | Viridans group streptococci |
| 1241 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftaroline | NA | - | - | F45 | G45 | FALSE | NA | Viridans group streptococci |
| 1242 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftazidime | NA | - | - | B46 | C46 | FALSE | NA | Viridans group streptococci |
| 1243 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftazidime | NA | - | - | F46 | G46 | FALSE | NA | Viridans group streptococci |
| 1244 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftazidime-avibactam | NA | - | - | B47 | C47 | FALSE | NA | Viridans group streptococci |
| 1245 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftazidime-avibactam | NA | - | - | F47 | G47 | FALSE | NA | Viridans group streptococci |
| 1246 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftibuten | NA | - | - | B48 | C48 | FALSE | NA | Viridans group streptococci |
| 1247 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftibuten | NA | - | - | F48 | G48 | FALSE | NA | Viridans group streptococci |
| 1248 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftobiprole | NA | - | - | B49 | C49 | FALSE | NA | Viridans group streptococci |
| 1249 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftobiprole | NA | - | - | F49 | G49 | FALSE | NA | Viridans group streptococci |
| 1250 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. anginosus group | Viridans group streptococci | NA | Ceftolozane-tazobactam | NA | IE | IE | B50 | C50 | FALSE | NA | Viridans group streptococci |
| 1251 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. anginosus group | Viridans group streptococci | NA | Ceftolozane-tazobactam | NA | IE | IE | F50 | G50 | FALSE | NA | Viridans group streptococci |
| 1252 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftriaxone | NA | 0.5 | 0.5 | B51 | C51 | FALSE | NA | Viridans group streptococci |
| 1253 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ceftriaxone | 30 mcg | 27 | 27 | F51 | G51 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1254 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefuroxime iv | NA | 0.5 | 0.5 | B52 | C52 | FALSE | NA | Viridans group streptococci |
| 1255 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefuroxime iv | 30 mcg | 26 | 26 | F52 | G52 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1256 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefuroxime oral | NA | - | - | B53 | C53 | FALSE | NA | Viridans group streptococci |
| 1257 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Cefuroxime oral | NA | - | - | F53 | G53 | FALSE | NA | Viridans group streptococci |
| 1258 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ertapenem | NA | 0.5 | 0.5 | B59 | C59 | FALSE | NA | Viridans group streptococci |
| 1259 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ertapenem | NA | Note | Note | F59 | G59 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1260 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Imipenem | NA | 2 | 2 | B60 | C60 | FALSE | NA | Viridans group streptococci |
| 1261 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Imipenem | NA | Note | Note | F60 | G60 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1262 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Meropenem | NA | 2 | 2 | B61 | C61 | FALSE | NA | Viridans group streptococci |
| 1263 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Meropenem | NA | Note | Note | F61 | G61 | FALSE | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins. | Viridans group streptococci |
| 1264 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Meropenem-vaborbactam | NA | IE | IE | B62 | C62 | FALSE | NA | Viridans group streptococci |
| 1265 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Meropenem-vaborbactam | NA | IE | IE | F62 | G62 | FALSE | NA | Viridans group streptococci |
| 1266 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Aztreonam | NA | - | - | B67 | C67 | FALSE | NA | Viridans group streptococci |
| 1267 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Aztreonam | NA | - | - | F67 | G67 | FALSE | NA | Viridans group streptococci |
| 1268 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ciprofloxacin | NA | - | - | B72 | C72 | FALSE | NA | Viridans group streptococci |
| 1269 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ciprofloxacin | NA | - | - | F72 | G72 | FALSE | NA | Viridans group streptococci |
| 1270 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Levofloxacin | NA | IE | IE | B73 | C73 | FALSE | NA | Viridans group streptococci |
| 1271 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Levofloxacin | NA | IE | IE | F73 | G73 | FALSE | NA | Viridans group streptococci |
| 1272 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Moxifloxacin | NA | IE | IE | B74 | C74 | FALSE | NA | Viridans group streptococci |
| 1273 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Moxifloxacin | NA | IE | IE | F74 | G74 | FALSE | NA | Viridans group streptococci |
| 1274 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Nalidixic acid (screen) | NA | NA | NA | B75 | C75 | FALSE | NA | Viridans group streptococci |
| 1275 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Nalidixic acid (screen) | NA | NA | NA | F75 | G75 | FALSE | NA | Viridans group streptococci |
| 1276 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | B76 | C76 | FALSE | NA | Viridans group streptococci |
| 1277 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | F76 | G76 | FALSE | NA | Viridans group streptococci |
| 1278 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Ofloxacin | NA | - | - | B77 | C77 | FALSE | NA | Viridans group streptococci |
| 1279 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Ofloxacin | NA | - | - | F77 | G77 | FALSE | NA | Viridans group streptococci |
| 1280 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Amikacin | NA | Note | Note | B82 | C82 | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides. | Viridans group streptococci |
| 1281 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Amikacin | NA | - | - | F82 | G82 | FALSE | NA | Viridans group streptococci |
| 1282 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Gentamicin (test for high-level aminoglycoside resistance) | NA | Note | Note | B83 | C83 | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides. | Viridans group streptococci |
| 1283 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Gentamicin (test for high-level aminoglycoside resistance) | NA | - | - | F83 | G83 | FALSE | NA | Viridans group streptococci |
| 1284 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Netilmicin | NA | Note | Note | B84 | C84 | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides. | Viridans group streptococci |
| 1285 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Netilmicin | NA | - | - | F84 | G84 | FALSE | NA | Viridans group streptococci |
| 1286 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Tobramycin | NA | Note | Note | B85 | C85 | FALSE | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides. | Viridans group streptococci |
| 1287 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Tobramycin | NA | - | - | F85 | G85 | FALSE | NA | Viridans group streptococci |
| 1288 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. anginosus group | Viridans group streptococci | NA | Dalbavancin | NA | 0.125 | 0.125 | B90 | C90 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1289 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. anginosus group | Viridans group streptococci | NA | Dalbavancin | NA | Note | Note | F90 | G90 | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1290 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. anginosus group | Viridans group streptococci | NA | Oritavancin | NA | 0.25 | 0.25 | B91 | C91 | FALSE | [2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1291 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. anginosus group | Viridans group streptococci | NA | Oritavancin | NA | Note | Note | F91 | G91 | FALSE | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1292 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Teicoplanin | NA | 2 | 2 | B92 | C92 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1293 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Teicoplanin | 30 mcg | 16 | 16 | F92 | G92 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1294 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Telavancin | NA | IE | IE | B93 | C93 | FALSE | NA | Viridans group streptococci |
| 1295 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Telavancin | NA | IE | IE | F93 | G93 | FALSE | NA | Viridans group streptococci |
| 1296 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Vancomycin | NA | 2 | 2 | B94 | C94 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1297 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Vancomycin | 5 mcg | 15 | 15 | F94 | G94 | FALSE | [B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | Viridans group streptococci |
| 1298 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Azithromycin | NA | IE | IE | B99 | C99 | FALSE | NA | Viridans group streptococci |
| 1299 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Azithromycin | NA | IE | IE | F99 | G99 | FALSE | NA | Viridans group streptococci |
| 1300 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Clarithromycin | NA | IE | IE | B100 | C100 | FALSE | NA | Viridans group streptococci |
| 1301 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Clarithromycin | NA | IE | IE | F100 | G100 | FALSE | NA | Viridans group streptococci |
| 1302 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Erythromycin | NA | IE | IE | B101 | C101 | FALSE | NA | Viridans group streptococci |
| 1303 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Erythromycin | 15 mcg | IE | IE | F101 | G101 | FALSE | NA | Viridans group streptococci |
| 1304 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Roxithromycin | NA | IE | IE | B102 | C102 | FALSE | NA | Viridans group streptococci |
| 1305 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Roxithromycin | NA | IE | IE | F102 | G102 | FALSE | NA | Viridans group streptococci |
| 1306 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Telithromycin | NA | IE | IE | B103 | C103 | FALSE | NA | Viridans group streptococci |
| 1307 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Telithromycin | NA | IE | IE | F103 | G103 | FALSE | NA | Viridans group streptococci |
| 1308 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Clindamycin | NA | 0.5 | 0.5 | B105 | C105 | FALSE | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | Viridans group streptococci |
| 1309 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Clindamycin | 2 mcg | 19 | 19 | F105 | G105 | FALSE | [A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant. | Viridans group streptococci |
| 1310 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Quinupristin-dalfopristin | NA | IE | IE | B106 | C106 | FALSE | NA | Viridans group streptococci |
| 1311 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Quinupristin-dalfopristin | NA | IE | IE | F106 | G106 | FALSE | NA | Viridans group streptococci |
| 1312 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Doxycycline | NA | - | - | B111 | C111 | FALSE | NA | Viridans group streptococci |
| 1313 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Doxycycline | NA | - | - | F111 | G111 | FALSE | NA | Viridans group streptococci |
| 1314 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Eravacycline | NA | 0.125 | 0.125 | B112 | C112 | FALSE | NA | Viridans group streptococci |
| 1315 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Eravacycline | IP mcg | IP | IP | F112 | G112 | FALSE | NA | Viridans group streptococci |
| 1316 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Minocycline | NA | - | - | B113 | C113 | FALSE | NA | Viridans group streptococci |
| 1317 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Minocycline | NA | - | - | F113 | G113 | FALSE | NA | Viridans group streptococci |
| 1318 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Tetracycline | NA | - | - | B114 | C114 | FALSE | NA | Viridans group streptococci |
| 1319 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Tetracycline | NA | - | - | F114 | G114 | FALSE | NA | Viridans group streptococci |
| 1320 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Tigecycline | NA | IE | IE | B115 | C115 | FALSE | NA | Viridans group streptococci |
| 1321 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Tigecycline | NA | IE | IE | F115 | G115 | FALSE | NA | Viridans group streptococci |
| 1322 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Linezolid | NA | - | - | B120 | C120 | FALSE | NA | Viridans group streptococci |
| 1323 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Linezolid | NA | - | - | F120 | G120 | FALSE | NA | Viridans group streptococci |
| 1324 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | S. anginosus group | Viridans group streptococci | NA | Tedizolid | NA | 0.25 | 0.25 | B121 | C121 | FALSE | NA | Viridans group streptococci |
| 1325 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | S. anginosus group | Viridans group streptococci | NA | Tedizolid | NA | Note | Note | F121 | G121 | FALSE | [A] Perform an MIC test. | Viridans group streptococci |
| 1326 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Chloramphenicol | NA | - | - | B126 | C126 | FALSE | NA | Viridans group streptococci |
| 1327 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Chloramphenicol | NA | - | - | F126 | G126 | FALSE | NA | Viridans group streptococci |
| 1328 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Colistin | NA | - | - | B127 | C127 | FALSE | NA | Viridans group streptococci |
| 1329 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Colistin | NA | - | - | F127 | G127 | FALSE | NA | Viridans group streptococci |
| 1330 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Daptomycin | NA | - | - | B128 | C128 | FALSE | NA | Viridans group streptococci |
| 1331 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Daptomycin | NA | - | - | F128 | G128 | FALSE | NA | Viridans group streptococci |
| 1332 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Fosfomycin iv | NA | - | - | B129 | C129 | FALSE | NA | Viridans group streptococci |
| 1333 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Fosfomycin iv | NA | - | - | F129 | G129 | FALSE | NA | Viridans group streptococci |
| 1334 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Fosfomycin oral | NA | - | - | B130 | C130 | FALSE | NA | Viridans group streptococci |
| 1335 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Fosfomycin oral | NA | - | - | F130 | G130 | FALSE | NA | Viridans group streptococci |
| 1336 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Fusidic acid | NA | - | - | B131 | C131 | FALSE | NA | Viridans group streptococci |
| 1337 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Fusidic acid | NA | - | - | F131 | G131 | FALSE | NA | Viridans group streptococci |
| 1338 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Metronidazole | NA | - | - | B132 | C132 | FALSE | NA | Viridans group streptococci |
| 1339 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Metronidazole | NA | - | - | F132 | G132 | FALSE | NA | Viridans group streptococci |
| 1340 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | B133 | C133 | FALSE | NA | Viridans group streptococci |
| 1341 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | F133 | G133 | FALSE | NA | Viridans group streptococci |
| 1342 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | B134 | C134 | FALSE | NA | Viridans group streptococci |
| 1343 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | F134 | G134 | FALSE | NA | Viridans group streptococci |
| 1344 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Rifampicin | NA | - | - | B135 | C135 | FALSE | NA | Viridans group streptococci |
| 1345 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Rifampicin | NA | - | - | F135 | G135 | FALSE | NA | Viridans group streptococci |
| 1346 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Spectinomycin | NA | - | - | B136 | C136 | FALSE | NA | Viridans group streptococci |
| 1347 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Spectinomycin | NA | - | - | F136 | G136 | FALSE | NA | Viridans group streptococci |
| 1348 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | B137 | C137 | FALSE | NA | Viridans group streptococci |
| 1349 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | F137 | G137 | FALSE | NA | Viridans group streptococci |
| 1350 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Viridans group streptococci | Viridans group streptococci | NA | Trimethoprim-sulfamethoxazole | NA | - | - | B138 | C138 | FALSE | NA | Viridans group streptococci |
| 1351 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Viridans group streptococci | Viridans group streptococci | NA | Trimethoprim-sulfamethoxazole | NA | - | - | F138 | G138 | FALSE | NA | Viridans group streptococci |
| 1352 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Benzylpenicillin | NA | IE | IE | B10 | C10 | FALSE | NA | H.influenzae |
| 1353 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Benzylpenicillin | NA | IE | IE | F10 | G10 | FALSE | NA | H.influenzae |
| 1354 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Benzylpenicillin (screen) | NA | NA | NA | B11 | C11 | FALSE | [1] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1355 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Benzylpenicillin (screen) | 1 unit | 12 | Note | F11 | G11 | FALSE | [1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1356 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ampicillin | NA | 1 | 1 | B12 | C12 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1357 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ampicillin | 2 mcg | 16 | 16 | F12 | G12 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1358 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ampicillin-sulbactam | NA | 1 | 1 | B13 | C13 | FALSE | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid. | H.influenzae |
| 1359 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ampicillin-sulbactam | 10/10 mcg | Note | Note | F13 | G13 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [C] Susceptibility can be inferred from amoxicillin-clavulanic acid. | H.influenzae |
| 1360 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amoxicillin iv | NA | 2 | 2 | B14 | C14 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1361 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amoxicillin iv | NA | Note | Note | F14 | G14 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1362 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amoxicillin oral | NA | 2 | 2 | B15 | C15 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | H.influenzae |
| 1363 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amoxicillin oral | NA | Note | Note | F15 | G15 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | H.influenzae |
| 1364 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid iv | NA | 2 | 2 | B16 | C16 | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | H.influenzae |
| 1365 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid iv | 2/1 mcg | 15 | 15 | F16 | G16 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1366 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid oral | NA | 2 | 2 | B17 | C17 | FALSE | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | H.influenzae |
| 1367 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amoxicillin-clavulanic acid oral | 2/1 mcg | 15 | 15 | F17 | G17 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table) | H.influenzae |
| 1368 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Piperacillin | NA | IE | IE | B18 | C18 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1369 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Piperacillin | NA | IE | IE | F18 | G18 | FALSE | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | H.influenzae |
| 1370 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Piperacillin-tazobactam | NA | 0.25 | 0.25 | B19 | C19 | FALSE | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | H.influenzae |
| 1371 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Piperacillin-tazobactam | 30/6 mcg | 27 | 27 | F19 | G19 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1372 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ticarcillin | NA | IE | IE | B20 | C20 | FALSE | NA | H.influenzae |
| 1373 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ticarcillin | NA | IE | IE | F20 | G20 | FALSE | NA | H.influenzae |
| 1374 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ticarcillin-clavulanic acid | NA | IE | IE | B21 | C21 | FALSE | NA | H.influenzae |
| 1375 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ticarcillin-clavulanic acid | NA | IE | IE | F21 | G21 | FALSE | NA | H.influenzae |
| 1376 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Temocillin | NA | IE | IE | B22 | C22 | FALSE | NA | H.influenzae |
| 1377 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Temocillin | NA | IE | IE | F22 | G22 | FALSE | NA | H.influenzae |
| 1378 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Phenoxymethylpenicillin | NA | IE | IE | B24 | C24 | FALSE | NA | H.influenzae |
| 1379 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Phenoxymethylpenicillin | NA | IE | IE | F24 | G24 | FALSE | NA | H.influenzae |
| 1380 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Oxacillin | NA | - | - | B26 | C26 | FALSE | NA | H.influenzae |
| 1381 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Oxacillin | NA | - | - | F26 | G26 | FALSE | NA | H.influenzae |
| 1382 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cloxacillin | NA | - | - | B27 | C27 | FALSE | NA | H.influenzae |
| 1383 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cloxacillin | NA | - | - | F27 | G27 | FALSE | NA | H.influenzae |
| 1384 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Dicloxacillin | NA | - | - | B28 | C28 | FALSE | NA | H.influenzae |
| 1385 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Dicloxacillin | NA | - | - | F28 | G28 | FALSE | NA | H.influenzae |
| 1386 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Flucloxacillin | NA | - | - | B29 | C29 | FALSE | NA | H.influenzae |
| 1387 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Flucloxacillin | NA | - | - | F29 | G29 | FALSE | NA | H.influenzae |
| 1388 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B31 | C31 | FALSE | NA | H.influenzae |
| 1389 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | F31 | G31 | FALSE | NA | H.influenzae |
| 1390 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefaclor | NA | - | - | B36 | C36 | FALSE | NA | H.influenzae |
| 1391 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefaclor | NA | - | - | F36 | G36 | FALSE | NA | H.influenzae |
| 1392 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefadroxil | NA | - | - | B37 | C37 | FALSE | NA | H.influenzae |
| 1393 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefadroxil | NA | - | - | F37 | G37 | FALSE | NA | H.influenzae |
| 1394 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefalexin | NA | - | - | B38 | C38 | FALSE | NA | H.influenzae |
| 1395 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefalexin | NA | - | - | F38 | G38 | FALSE | NA | H.influenzae |
| 1396 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefazolin | NA | - | - | B39 | C39 | FALSE | NA | H.influenzae |
| 1397 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefazolin | NA | - | - | F39 | G39 | FALSE | NA | H.influenzae |
| 1398 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefepime | NA | 0.25 | 0.25 | B40 | C40 | FALSE | NA | H.influenzae |
| 1399 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefepime | 30 mcg | 28 | 28 | F40 | G40 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 1400 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefixime | NA | 0.125 | 0.125 | B41 | C41 | FALSE | NA | H.influenzae |
| 1401 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefixime | 5 mcg | 26 | 26 | F41 | G41 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1402 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefotaxime | NA | 0.125 | 0.125 | B42 | C42 | FALSE | NA | H.influenzae |
| 1403 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefotaxime | 5 mcg | 27 | 27 | F42 | G42 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1404 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefoxitin | NA | NA | NA | B43 | C43 | FALSE | NA | H.influenzae |
| 1405 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefoxitin | NA | NA | NA | F43 | G43 | FALSE | NA | H.influenzae |
| 1406 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefpodoxime | NA | 0.25 | 0.25 | B44 | C44 | FALSE | NA | H.influenzae |
| 1407 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefpodoxime | 10 mcg | 26 | 26 | F44 | G44 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | H.influenzae |
| 1408 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftaroline | NA | 0.03 | 0.03 | B45 | C45 | FALSE | NA | H.influenzae |
| 1409 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftaroline | NA | Note | Note | F45 | G45 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1410 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftazidime | NA | - | - | B46 | C46 | FALSE | NA | H.influenzae |
| 1411 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftazidime | NA | - | - | F46 | G46 | FALSE | NA | H.influenzae |
| 1412 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftazidime-avibactam | NA | - | - | B47 | C47 | FALSE | NA | H.influenzae |
| 1413 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftazidime-avibactam | NA | - | - | F47 | G47 | FALSE | NA | H.influenzae |
| 1414 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftibuten | NA | 1 | 1 | B48 | C48 | FALSE | NA | H.influenzae |
| 1415 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftibuten | 30 mcg | 25 | 25 | F48 | G48 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1416 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftobiprole | NA | IE | IE | B49 | C49 | FALSE | NA | H.influenzae |
| 1417 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftobiprole | NA | IE | IE | F49 | G49 | FALSE | NA | H.influenzae |
| 1418 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftolozane-tazobactam | NA | IE | IE | B50 | C50 | FALSE | NA | H.influenzae |
| 1419 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftolozane-tazobactam | NA | IE | IE | F50 | G50 | FALSE | NA | H.influenzae |
| 1420 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftriaxone | NA | 0.125 | 0.125 | B51 | C51 | FALSE | NA | H.influenzae |
| 1421 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ceftriaxone | 30 mcg | 32 | 32 | F51 | G51 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1422 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefuroxime iv | NA | 1 | 2 | B52 | C52 | FALSE | NA | H.influenzae |
| 1423 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefuroxime iv | 30 mcg | 27 | 25 | F52 | G52 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | H.influenzae |
| 1424 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefuroxime oral | NA | 0.125 | 1 | B53 | C53 | FALSE | NA | H.influenzae |
| 1425 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Cefuroxime oral | 30 mcg | 50 | 27 | F53 | G53 | FALSE | NA | H.influenzae |
| 1426 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ertapenem | NA | 0.5 | 0.5 | B59 | C59 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 1427 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ertapenem | 10 mcg | 23 | 23 | F59 | G59 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 1428 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Imipenem | NA | 2 | 2 | B60 | C60 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 1429 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Imipenem | 10 mcg | 20 | 20 | F60 | G60 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 1430 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Meropenem (indications other than meningitis) | NA | 2 | 2 | B61 | C61 | FALSE | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 1431 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Meropenem (indications other than meningitis) | 10 mcg | 20 | 20 | F61 | G61 | FALSE | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis). | H.influenzae |
| 1432 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Meropenem(meningitis) | NA | 0.25 | 0.25 | B62 | C62 | FALSE | [3] Meropenem is the only carbapenem used for meningitis. | H.influenzae |
| 1433 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Meropenem(meningitis) | NA | Note | Note | F62 | G62 | FALSE | [C] For use in meningitis determine the meropenem MIC value. | [3] Meropenem is the only carbapenem used for meningitis. | H.influenzae |
| 1434 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Meropenem-vaborbactam | NA | IE | IE | B63 | C63 | FALSE | NA | H.influenzae |
| 1435 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Meropenem-vaborbactam | NA | IE | IE | F63 | G63 | FALSE | NA | H.influenzae |
| 1436 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Aztreonam | NA | IE | IE | B68 | C68 | FALSE | NA | H.influenzae |
| 1437 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Aztreonam | NA | IE | IE | F68 | G68 | FALSE | NA | H.influenzae |
| 1438 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ciprofloxacin | NA | 0.06 | 0.06 | B73 | C73 | FALSE | NA | H.influenzae |
| 1439 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ciprofloxacin | 5 mcg | 30 | 30 | F73 | G73 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | H.influenzae |
| 1440 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Levofloxacin | NA | 0.06 | 0.06 | B74 | C74 | FALSE | NA | H.influenzae |
| 1441 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Levofloxacin | 5 mcg | 30 | 30 | F74 | G74 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | H.influenzae |
| 1442 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Moxifloxacin | NA | 0.125 | 0.125 | B75 | C75 | FALSE | NA | H.influenzae |
| 1443 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Moxifloxacin | 5 mcg | 28 | 28 | F75 | G75 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | H.influenzae |
| 1444 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Nalidixic acid (screen) | NA | NA | NA | B76 | C76 | FALSE | NA | H.influenzae |
| 1445 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Nalidixic acid (screen) | 30 mcg | 23 | Note | F76 | G76 | FALSE | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. | H.influenzae |
| 1446 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | B77 | C77 | FALSE | NA | H.influenzae |
| 1447 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | F77 | G77 | FALSE | NA | H.influenzae |
| 1448 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ofloxacin | NA | 0.06 | 0.06 | B78 | C78 | FALSE | NA | H.influenzae |
| 1449 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Ofloxacin | 5 mcg | 30 | 30 | F78 | G78 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | H.influenzae |
| 1450 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amikacin | NA | IE | IE | B83 | C83 | FALSE | NA | H.influenzae |
| 1451 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Amikacin | NA | IE | IE | F83 | G83 | FALSE | NA | H.influenzae |
| 1452 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Gentamicin | NA | IE | IE | B84 | C84 | FALSE | NA | H.influenzae |
| 1453 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Gentamicin | NA | IE | IE | F84 | G84 | FALSE | NA | H.influenzae |
| 1454 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Netilmicin | NA | IE | IE | B85 | C85 | FALSE | NA | H.influenzae |
| 1455 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Netilmicin | NA | IE | IE | F85 | G85 | FALSE | NA | H.influenzae |
| 1456 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Tobramycin | NA | IE | IE | B86 | C86 | FALSE | NA | H.influenzae |
| 1457 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Tobramycin | NA | IE | IE | F86 | G86 | FALSE | NA | H.influenzae |
| 1458 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Dalbavancin | NA | - | - | B91 | C91 | FALSE | NA | H.influenzae |
| 1459 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Dalbavancin | NA | - | - | F91 | G91 | FALSE | NA | H.influenzae |
| 1460 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Oritavancin | NA | - | - | B92 | C92 | FALSE | NA | H.influenzae |
| 1461 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Oritavancin | NA | - | - | F92 | G92 | FALSE | NA | H.influenzae |
| 1462 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Teicoplanin | NA | - | - | B93 | C93 | FALSE | NA | H.influenzae |
| 1463 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Teicoplanin | NA | - | - | F93 | G93 | FALSE | NA | H.influenzae |
| 1464 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Telavancin | NA | - | - | B94 | C94 | FALSE | NA | H.influenzae |
| 1465 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Telavancin | NA | - | - | F94 | G94 | FALSE | NA | H.influenzae |
| 1466 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Vancomycin | NA | - | - | B95 | C95 | FALSE | NA | H.influenzae |
| 1467 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Vancomycin | NA | - | - | F95 | G95 | FALSE | NA | H.influenzae |
| 1468 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Azithromycin | NA | Note | Note | B100 | C100 | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1469 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Azithromycin | NA | Note | Note | F100 | G100 | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1470 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Clarithromycin | NA | Note | Note | B101 | C101 | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1471 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Clarithromycin | NA | Note | Note | F101 | G101 | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1472 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Erythromycin | NA | Note | Note | B102 | C102 | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1473 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Erythromycin | NA | Note | Note | F102 | G102 | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1474 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Roxithromycin | NA | Note | Note | B103 | C103 | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1475 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Roxithromycin | NA | Note | Note | F103 | G103 | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1476 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Telithromycin | NA | Note | Note | B104 | C104 | FALSE | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1477 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Telithromycin | NA | Note | Note | F104 | G104 | FALSE | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin. | H.influenzae |
| 1478 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Clindamycin | NA | - | - | B106 | C106 | FALSE | NA | H.influenzae |
| 1479 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Clindamycin | NA | - | - | F106 | G106 | FALSE | NA | H.influenzae |
| 1480 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Quinupristin-dalfopristin | NA | - | - | B107 | C107 | FALSE | NA | H.influenzae |
| 1481 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Quinupristin-dalfopristin | NA | - | - | F107 | G107 | FALSE | NA | H.influenzae |
| 1482 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Doxycycline | NA | 1 | 2 | B112 | C112 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1483 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Doxycycline | NA | Note | Note | F112 | G112 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1484 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Eravacycline | NA | IE | IE | B113 | C113 | FALSE | NA | H.influenzae |
| 1485 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Eravacycline | NA | IE | IE | F113 | G113 | FALSE | NA | H.influenzae |
| 1486 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Minocycline | NA | 1 | 2 | B114 | C114 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1487 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Minocycline | 30 mcg | 24 | 21 | F114 | G114 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1488 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Tetracycline | NA | 1 | 2 | B115 | C115 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1489 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Tetracycline | 30 mcg | 25 | 22 | F115 | G115 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | H.influenzae |
| 1490 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Tigecycline | NA | IE | IE | B116 | C116 | FALSE | NA | H.influenzae |
| 1491 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Tigecycline | NA | IE | IE | F116 | G116 | FALSE | NA | H.influenzae |
| 1492 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Linezolid | NA | - | - | B121 | C121 | FALSE | NA | H.influenzae |
| 1493 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Linezolid | NA | - | - | F121 | G121 | FALSE | NA | H.influenzae |
| 1494 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Tedizolid | NA | - | - | B122 | C122 | FALSE | NA | H.influenzae |
| 1495 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Tedizolid | NA | - | - | F122 | G122 | FALSE | NA | H.influenzae |
| 1496 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Chloramphenicol | NA | 2 | 2 | B127 | C127 | FALSE | NA | H.influenzae |
| 1497 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Chloramphenicol | 30 mcg | 28 | 28 | F127 | G127 | FALSE | NA | H.influenzae |
| 1498 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Colistin | NA | - | - | B128 | C128 | FALSE | NA | H.influenzae |
| 1499 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Colistin | NA | - | - | F128 | G128 | FALSE | NA | H.influenzae |
| 1500 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Daptomycin | NA | - | - | B129 | C129 | FALSE | NA | H.influenzae |
| 1501 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Daptomycin | NA | - | - | F129 | G129 | FALSE | NA | H.influenzae |
| 1502 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Fosfomycin iv | NA | IE | IE | B130 | C130 | FALSE | NA | H.influenzae |
| 1503 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Fosfomycin iv | NA | IE | IE | F130 | G130 | FALSE | NA | H.influenzae |
| 1504 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Fosfomycin oral | NA | - | - | B131 | C131 | FALSE | NA | H.influenzae |
| 1505 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Fosfomycin oral | NA | - | - | F131 | G131 | FALSE | NA | H.influenzae |
| 1506 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Fusidic acid | NA | - | - | B132 | C132 | FALSE | NA | H.influenzae |
| 1507 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Fusidic acid | NA | - | - | F132 | G132 | FALSE | NA | H.influenzae |
| 1508 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Metronidazole | NA | - | - | B133 | C133 | FALSE | NA | H.influenzae |
| 1509 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Metronidazole | NA | - | - | F133 | G133 | FALSE | NA | H.influenzae |
| 1510 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | B134 | C134 | FALSE | NA | H.influenzae |
| 1511 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | F134 | G134 | FALSE | NA | H.influenzae |
| 1512 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | B135 | C135 | FALSE | NA | H.influenzae |
| 1513 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | F135 | G135 | FALSE | NA | H.influenzae |
| 1514 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Rifampicin (for prophylaxis only) | NA | 1 | 1 | B136 | C136 | FALSE | NA | H.influenzae |
| 1515 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Rifampicin (for prophylaxis only) | 5 mcg | 18 | 18 | F136 | G136 | FALSE | NA | H.influenzae |
| 1516 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Spectinomycin | NA | - | - | B137 | C137 | FALSE | NA | H.influenzae |
| 1517 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Spectinomycin | NA | - | - | F137 | G137 | FALSE | NA | H.influenzae |
| 1518 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | B138 | C138 | FALSE | NA | H.influenzae |
| 1519 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | F138 | G138 | FALSE | NA | H.influenzae |
| 1520 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Trimethoprim-sulfamethoxazole | NA | 0.5 | 1 | B139 | C139 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | H.influenzae |
| 1521 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Haemophilus influenzae | Haemophilus influenzae | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 23 | 20 | F139 | G139 | FALSE | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | H.influenzae |
| 1522 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Benzylpenicillin | NA | - | - | B8 | C8 | FALSE | NA | M.catarrhalis |
| 1523 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Benzylpenicillin | NA | - | - | F8 | G8 | FALSE | NA | M.catarrhalis |
| 1524 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ampicillin | NA | - | - | B9 | C9 | FALSE | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors. | M.catarrhalis |
| 1525 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ampicillin | NA | - | - | F9 | G9 | FALSE | NA | M.catarrhalis |
| 1526 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ampicillin-sulbactam | NA | 1 | 1 | B10 | C10 | FALSE | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 1527 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ampicillin-sulbactam | NA | Note | Note | F10 | G10 | FALSE | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 1528 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Amoxicillin | NA | - | - | B11 | C11 | FALSE | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors. | M.catarrhalis |
| 1529 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Amoxicillin | NA | - | - | F11 | G11 | FALSE | NA | M.catarrhalis |
| 1530 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Amoxicillin-clavulanic acid | NA | 1 | 1 | B12 | C12 | FALSE | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | M.catarrhalis |
| 1531 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Amoxicillin-clavulanic acid | 2/1 mcg | 19 | 19 | F12 | G12 | FALSE | NA | M.catarrhalis |
| 1532 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Piperacillin | NA | - | - | B13 | C13 | FALSE | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors. | M.catarrhalis |
| 1533 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Piperacillin | NA | - | - | F13 | G13 | FALSE | NA | M.catarrhalis |
| 1534 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Piperacillin-tazobactam | NA | Note | Note | B14 | C14 | FALSE | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 1535 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Piperacillin-tazobactam | NA | Note | Note | F14 | G14 | FALSE | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid. | M.catarrhalis |
| 1536 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ticarcillin | NA | IE | IE | B15 | C15 | FALSE | NA | M.catarrhalis |
| 1537 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ticarcillin | NA | IE | IE | F15 | G15 | FALSE | NA | M.catarrhalis |
| 1538 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ticarcillin-clavulanic acid | NA | IE | IE | B16 | C16 | FALSE | NA | M.catarrhalis |
| 1539 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ticarcillin-clavulanic acid | NA | IE | IE | F16 | G16 | FALSE | NA | M.catarrhalis |
| 1540 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Temocillin | NA | IE | IE | B17 | C17 | FALSE | NA | M.catarrhalis |
| 1541 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Temocillin | NA | IE | IE | F17 | G17 | FALSE | NA | M.catarrhalis |
| 1542 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Phenoxymethylpenicillin | NA | - | - | B19 | C19 | FALSE | NA | M.catarrhalis |
| 1543 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Phenoxymethylpenicillin | NA | - | - | F19 | G19 | FALSE | NA | M.catarrhalis |
| 1544 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Oxacillin | NA | - | - | B21 | C21 | FALSE | NA | M.catarrhalis |
| 1545 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Oxacillin | NA | - | - | F21 | G21 | FALSE | NA | M.catarrhalis |
| 1546 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cloxacillin | NA | - | - | B22 | C22 | FALSE | NA | M.catarrhalis |
| 1547 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cloxacillin | NA | - | - | F22 | G22 | FALSE | NA | M.catarrhalis |
| 1548 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Dicloxacillin | NA | - | - | B23 | C23 | FALSE | NA | M.catarrhalis |
| 1549 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Dicloxacillin | NA | - | - | F23 | G23 | FALSE | NA | M.catarrhalis |
| 1550 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Flucloxacillin | NA | - | - | B24 | C24 | FALSE | NA | M.catarrhalis |
| 1551 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Flucloxacillin | NA | - | - | F24 | G24 | FALSE | NA | M.catarrhalis |
| 1552 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B26 | C26 | FALSE | NA | M.catarrhalis |
| 1553 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | F26 | G26 | FALSE | NA | M.catarrhalis |
| 1554 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefaclor | NA | - | - | B31 | C31 | FALSE | NA | M.catarrhalis |
| 1555 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefaclor | NA | - | - | F31 | G31 | FALSE | NA | M.catarrhalis |
| 1556 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefadroxil | NA | - | - | B32 | C32 | FALSE | NA | M.catarrhalis |
| 1557 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefadroxil | NA | - | - | F32 | G32 | FALSE | NA | M.catarrhalis |
| 1558 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefalexin | NA | - | - | B33 | C33 | FALSE | NA | M.catarrhalis |
| 1559 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefalexin | NA | - | - | F33 | G33 | FALSE | NA | M.catarrhalis |
| 1560 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefazolin | NA | - | - | B34 | C34 | FALSE | NA | M.catarrhalis |
| 1561 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefazolin | NA | - | - | F34 | G34 | FALSE | NA | M.catarrhalis |
| 1562 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefepime | NA | 4 | 4 | B35 | C35 | FALSE | NA | M.catarrhalis |
| 1563 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefepime | 30 mcg | 20 | 20 | F35 | G35 | FALSE | NA | M.catarrhalis |
| 1564 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefixime | NA | 0.5 | 1 | B36 | C36 | FALSE | NA | M.catarrhalis |
| 1565 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefixime | 5 mcg | 21 | 18 | F36 | G36 | FALSE | NA | M.catarrhalis |
| 1566 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefotaxime | NA | 1 | 2 | B37 | C37 | FALSE | NA | M.catarrhalis |
| 1567 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefotaxime | 5 mcg | 20 | 17 | F37 | G37 | FALSE | NA | M.catarrhalis |
| 1568 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefoxitin | NA | NA | NA | B38 | C38 | FALSE | NA | M.catarrhalis |
| 1569 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefoxitin | NA | NA | NA | F38 | G38 | FALSE | NA | M.catarrhalis |
| 1570 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefpodoxime | NA | IP | IP | B39 | C39 | FALSE | NA | M.catarrhalis |
| 1571 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefpodoxime | 10 mcg | IP | IP | F39 | G39 | FALSE | NA | M.catarrhalis |
| 1572 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftaroline | NA | IE | IE | B40 | C40 | FALSE | NA | M.catarrhalis |
| 1573 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftaroline | NA | IE | IE | F40 | G40 | FALSE | NA | M.catarrhalis |
| 1574 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftazidime | NA | - | - | B41 | C41 | FALSE | NA | M.catarrhalis |
| 1575 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftazidime | NA | - | - | F41 | G41 | FALSE | NA | M.catarrhalis |
| 1576 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftazidime-avibactam | NA | - | - | B42 | C42 | FALSE | NA | M.catarrhalis |
| 1577 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftazidime-avibactam | NA | - | - | F42 | G42 | FALSE | NA | M.catarrhalis |
| 1578 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftibuten | NA | IE | IE | B43 | C43 | FALSE | NA | M.catarrhalis |
| 1579 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftibuten | NA | IE | IE | F43 | G43 | FALSE | NA | M.catarrhalis |
| 1580 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftobiprole | NA | IE | IE | B44 | C44 | FALSE | NA | M.catarrhalis |
| 1581 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftobiprole | NA | IE | IE | F44 | G44 | FALSE | NA | M.catarrhalis |
| 1582 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftolozane-tazobactam | NA | IE | IE | B45 | C45 | FALSE | NA | M.catarrhalis |
| 1583 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftolozane-tazobactam | NA | IE | IE | F45 | G45 | FALSE | NA | M.catarrhalis |
| 1584 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftriaxone | NA | 1 | 2 | B46 | C46 | FALSE | NA | M.catarrhalis |
| 1585 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ceftriaxone | 30 mcg | 24 | 21 | F46 | G46 | FALSE | NA | M.catarrhalis |
| 1586 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefuroxime iv | NA | 4 | 8 | B47 | C47 | FALSE | NA | M.catarrhalis |
| 1587 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefuroxime iv | 30 mcg | 21 | 18 | F47 | G47 | FALSE | NA | M.catarrhalis |
| 1588 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefuroxime oral | NA | 0.125 | 4 | B48 | C48 | FALSE | NA | M.catarrhalis |
| 1589 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Cefuroxime oral | 30 mcg | 50 | 21 | F48 | G48 | FALSE | NA | M.catarrhalis |
| 1590 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ertapenem | NA | 0.5 | 0.5 | B54 | C54 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 1591 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ertapenem | 10 mcg | 29 | 29 | F54 | G54 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 1592 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Imipenem | NA | 2 | 2 | B55 | C55 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 1593 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Imipenem | 10 mcg | 29 | 29 | F55 | G55 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 1594 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Meropenem | NA | 2 | 2 | B56 | C56 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 1595 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Meropenem | 10 mcg | 33 | 33 | F56 | G56 | FALSE | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | M.catarrhalis |
| 1596 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Meropenem-vaborbactam | NA | IE | IE | B57 | C57 | FALSE | NA | M.catarrhalis |
| 1597 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Meropenem-vaborbactam | NA | IE | IE | F57 | G57 | FALSE | NA | M.catarrhalis |
| 1598 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Aztreonam | NA | IE | IE | B62 | C62 | FALSE | NA | M.catarrhalis |
| 1599 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Aztreonam | NA | IE | IE | F62 | G62 | FALSE | NA | M.catarrhalis |
| 1600 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ciprofloxacin | NA | 0.125 | 0.125 | B67 | C67 | FALSE | NA | M.catarrhalis |
| 1601 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ciprofloxacin | 5 mcg | 31 | 31 | F67 | G67 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | M.catarrhalis |
| 1602 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Levofloxacin | NA | 0.125 | 0.125 | B68 | C68 | FALSE | NA | M.catarrhalis |
| 1603 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Levofloxacin | 5 mcg | 29 | 29 | F68 | G68 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | M.catarrhalis |
| 1604 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Moxifloxacin | NA | 0.25 | 0.25 | B69 | C69 | FALSE | NA | M.catarrhalis |
| 1605 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Moxifloxacin | 5 mcg | 26 | 26 | F69 | G69 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | M.catarrhalis |
| 1606 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Nalidixic acid (screen) | NA | NA | NA | B70 | C70 | FALSE | NA | M.catarrhalis |
| 1607 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Nalidixic acid (screen) | 30 mcg | 23 | Note | F70 | G70 | FALSE | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent. | M.catarrhalis |
| 1608 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | B71 | C71 | FALSE | NA | M.catarrhalis |
| 1609 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | F71 | G71 | FALSE | NA | M.catarrhalis |
| 1610 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ofloxacin | NA | 0.25 | 0.25 | B72 | C72 | FALSE | NA | M.catarrhalis |
| 1611 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Ofloxacin | 5 mcg | 28 | 28 | F72 | G72 | FALSE | [A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | M.catarrhalis |
| 1612 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Amikacin | NA | IE | IE | B77 | C77 | FALSE | NA | M.catarrhalis |
| 1613 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Amikacin | NA | IE | IE | F77 | G77 | FALSE | NA | M.catarrhalis |
| 1614 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Gentamicin | NA | IE | IE | B78 | C78 | FALSE | NA | M.catarrhalis |
| 1615 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Gentamicin | NA | IE | IE | F78 | G78 | FALSE | NA | M.catarrhalis |
| 1616 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Netilmicin | NA | IE | IE | B79 | C79 | FALSE | NA | M.catarrhalis |
| 1617 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Netilmicin | NA | IE | IE | F79 | G79 | FALSE | NA | M.catarrhalis |
| 1618 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Tobramycin | NA | IE | IE | B80 | C80 | FALSE | NA | M.catarrhalis |
| 1619 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Tobramycin | NA | IE | IE | F80 | G80 | FALSE | NA | M.catarrhalis |
| 1620 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Dalbavancin | NA | - | - | B85 | C85 | FALSE | NA | M.catarrhalis |
| 1621 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Dalbavancin | NA | - | - | F85 | G85 | FALSE | NA | M.catarrhalis |
| 1622 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Oritavancin | NA | - | - | B86 | C86 | FALSE | NA | M.catarrhalis |
| 1623 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Oritavancin | NA | - | - | F86 | G86 | FALSE | NA | M.catarrhalis |
| 1624 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Teicoplanin | NA | - | - | B87 | C87 | FALSE | NA | M.catarrhalis |
| 1625 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Teicoplanin | NA | - | - | F87 | G87 | FALSE | NA | M.catarrhalis |
| 1626 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Telavancin | NA | - | - | B88 | C88 | FALSE | NA | M.catarrhalis |
| 1627 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Telavancin | NA | - | - | F88 | G88 | FALSE | NA | M.catarrhalis |
| 1628 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Vancomycin | NA | - | - | B89 | C89 | FALSE | NA | M.catarrhalis |
| 1629 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Vancomycin | NA | - | - | F89 | G89 | FALSE | NA | M.catarrhalis |
| 1630 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Azithromycin | NA | 0.25 | 0.5 | B94 | C94 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 1631 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Azithromycin | NA | Note | Note | F94 | G94 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 1632 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Clarithromycin | NA | 0.25 | 0.5 | B95 | C95 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 1633 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Clarithromycin | NA | Note | Note | F95 | G95 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 1634 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Erythromycin | NA | 0.25 | 0.5 | B96 | C96 | FALSE | NA | M.catarrhalis |
| 1635 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Erythromycin | 15 mcg | 23 | 20 | F96 | G96 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 1636 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Roxithromycin | NA | 0.5 | 1 | B97 | C97 | FALSE | [1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 1637 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Roxithromycin | NA | Note | Note | F97 | G97 | FALSE | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin. | M.catarrhalis |
| 1638 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Telithromycin | NA | 0.25 | 0.5 | B98 | C98 | FALSE | NA | M.catarrhalis |
| 1639 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Telithromycin | 15 mcg | 23 | 20 | F98 | G98 | FALSE | NA | M.catarrhalis |
| 1640 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Clindamycin | NA | - | - | B100 | C100 | FALSE | NA | M.catarrhalis |
| 1641 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Clindamycin | NA | - | - | F100 | G100 | FALSE | NA | M.catarrhalis |
| 1642 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Quinupristin-dalfopristin | NA | - | - | B101 | C101 | FALSE | NA | M.catarrhalis |
| 1643 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Quinupristin-dalfopristin | NA | - | - | F101 | G101 | FALSE | NA | M.catarrhalis |
| 1644 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Doxycycline | NA | 1 | 2 | B106 | C106 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 1645 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Doxycycline | NA | Note | Note | F106 | G106 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 1646 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Eravacycline | NA | IE | IE | B107 | C107 | FALSE | NA | M.catarrhalis |
| 1647 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Eravacycline | NA | IE | IE | F107 | G107 | FALSE | NA | M.catarrhalis |
| 1648 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Minocycline | NA | 1 | 2 | B108 | C108 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 1649 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Minocycline | 30 mcg | 25 | 22 | F108 | G108 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 1650 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Tetracycline | NA | 1 | 2 | B109 | C109 | FALSE | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 1651 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Tetracycline | 30 mcg | 28 | 25 | F109 | G109 | FALSE | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required. | M.catarrhalis |
| 1652 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Tigecycline | NA | IE | IE | B110 | C110 | FALSE | NA | M.catarrhalis |
| 1653 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Tigecycline | NA | IE | IE | F110 | G110 | FALSE | NA | M.catarrhalis |
| 1654 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Linezolid | NA | - | - | B115 | C115 | FALSE | NA | M.catarrhalis |
| 1655 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Linezolid | NA | - | - | F115 | G115 | FALSE | NA | M.catarrhalis |
| 1656 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Tedizolid | NA | - | - | B116 | C116 | FALSE | NA | M.catarrhalis |
| 1657 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Tedizolid | NA | - | - | F116 | G116 | FALSE | NA | M.catarrhalis |
| 1658 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Chloramphenicol | NA | 2 | 2 | B121 | C121 | FALSE | [1] Breakpoints relate to topical use only. | M.catarrhalis |
| 1659 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Chloramphenicol | 30 mcg | 30 | 30 | F121 | G121 | FALSE | [A] Breakpoints relate to topical use only. | M.catarrhalis |
| 1660 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Colistin | NA | - | - | B122 | C122 | FALSE | NA | M.catarrhalis |
| 1661 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Colistin | NA | - | - | F122 | G122 | FALSE | NA | M.catarrhalis |
| 1662 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Daptomycin | NA | - | - | B123 | C123 | FALSE | NA | M.catarrhalis |
| 1663 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Daptomycin | NA | - | - | F123 | G123 | FALSE | NA | M.catarrhalis |
| 1664 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Fosfomycin iv | NA | IE | IE | B124 | C124 | FALSE | NA | M.catarrhalis |
| 1665 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Fosfomycin iv | NA | IE | IE | F124 | G124 | FALSE | NA | M.catarrhalis |
| 1666 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Fosfomycin oral | NA | - | - | B125 | C125 | FALSE | NA | M.catarrhalis |
| 1667 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Fosfomycin oral | NA | - | - | F125 | G125 | FALSE | NA | M.catarrhalis |
| 1668 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Fusidic acid | NA | - | - | B126 | C126 | FALSE | NA | M.catarrhalis |
| 1669 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Fusidic acid | NA | - | - | F126 | G126 | FALSE | NA | M.catarrhalis |
| 1670 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Metronidazole | NA | - | - | B127 | C127 | FALSE | NA | M.catarrhalis |
| 1671 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Metronidazole | NA | - | - | F127 | G127 | FALSE | NA | M.catarrhalis |
| 1672 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | B128 | C128 | FALSE | NA | M.catarrhalis |
| 1673 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | F128 | G128 | FALSE | NA | M.catarrhalis |
| 1674 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | B129 | C129 | FALSE | NA | M.catarrhalis |
| 1675 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | F129 | G129 | FALSE | NA | M.catarrhalis |
| 1676 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Rifampicin | NA | - | - | B130 | C130 | FALSE | NA | M.catarrhalis |
| 1677 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Rifampicin | NA | - | - | F130 | G130 | FALSE | NA | M.catarrhalis |
| 1678 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Spectinomycin | NA | - | - | B131 | C131 | FALSE | NA | M.catarrhalis |
| 1679 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Spectinomycin | NA | - | - | F131 | G131 | FALSE | NA | M.catarrhalis |
| 1680 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | B132 | C132 | FALSE | NA | M.catarrhalis |
| 1681 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Trimethoprim (uncomplicated UTI only) | NA | - | - | F132 | G132 | FALSE | NA | M.catarrhalis |
| 1682 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Trimethoprim-sulfamethoxazole | NA | 0.5 | 1 | B133 | C133 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | M.catarrhalis |
| 1683 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | DISK | NA | Moraxella catarrhalis | Moraxella catarrhalis | NA | Trimethoprim-sulfamethoxazole | 1.25/23.75 mcg | 18 | 15 | F133 | G133 | FALSE | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | M.catarrhalis |
| 1684 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Benzylpenicillin | NA | 0.06 | 1 | B10 | C10 | FALSE | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin. | N.gonorrhoeae |
| 1685 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ampicillin | NA | Note | Note | B11 | C11 | FALSE | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin. | N.gonorrhoeae |
| 1686 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ampicillin-sulbactam | NA | IE | IE | B12 | C12 | FALSE | NA | N.gonorrhoeae |
| 1687 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Amoxicillin | NA | Note | Note | B13 | C13 | FALSE | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin. | N.gonorrhoeae |
| 1688 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Amoxicillin-clavulanic acid | NA | Note | Note | B14 | C14 | FALSE | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin. | N.gonorrhoeae |
| 1689 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Piperacillin | NA | - | - | B15 | C15 | FALSE | NA | N.gonorrhoeae |
| 1690 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Piperacillin-tazobactam | NA | - | - | B16 | C16 | FALSE | NA | N.gonorrhoeae |
| 1691 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ticarcillin | NA | - | - | B17 | C17 | FALSE | NA | N.gonorrhoeae |
| 1692 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ticarcillin-clavulanic acid | NA | - | - | B18 | C18 | FALSE | NA | N.gonorrhoeae |
| 1693 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Temocillin | NA | IE | IE | B19 | C19 | FALSE | NA | N.gonorrhoeae |
| 1694 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Phenoxymethylpenicillin | NA | - | - | B21 | C21 | FALSE | NA | N.gonorrhoeae |
| 1695 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Oxacillin | NA | - | - | B23 | C23 | FALSE | NA | N.gonorrhoeae |
| 1696 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cloxacillin | NA | - | - | B24 | C24 | FALSE | NA | N.gonorrhoeae |
| 1697 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Dicloxacillin | NA | - | - | B25 | C25 | FALSE | NA | N.gonorrhoeae |
| 1698 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Flucloxacillin | NA | - | - | B26 | C26 | FALSE | NA | N.gonorrhoeae |
| 1699 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Mecillinam (uncomplicated UTI only) | NA | - | - | B28 | C28 | FALSE | NA | N.gonorrhoeae |
| 1700 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefaclor | NA | - | - | B33 | C33 | FALSE | NA | N.gonorrhoeae |
| 1701 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefadroxil | NA | - | - | B34 | C34 | FALSE | NA | N.gonorrhoeae |
| 1702 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefalexin | NA | - | - | B35 | C35 | FALSE | NA | N.gonorrhoeae |
| 1703 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefazolin | NA | - | - | B36 | C36 | FALSE | NA | N.gonorrhoeae |
| 1704 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefepime | NA | - | - | B37 | C37 | FALSE | NA | N.gonorrhoeae |
| 1705 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefixime | NA | 0.125 | 0.125 | B38 | C38 | FALSE | NA | N.gonorrhoeae |
| 1706 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefotaxime | NA | 0.125 | 0.125 | B39 | C39 | FALSE | NA | N.gonorrhoeae |
| 1707 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefoxitin | NA | - | - | B40 | C40 | FALSE | NA | N.gonorrhoeae |
| 1708 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefpodoxime | NA | - | - | B41 | C41 | FALSE | NA | N.gonorrhoeae |
| 1709 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ceftaroline | NA | - | - | B42 | C42 | FALSE | NA | N.gonorrhoeae |
| 1710 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ceftazidime | NA | - | - | B43 | C43 | FALSE | NA | N.gonorrhoeae |
| 1711 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ceftazidime-avibactam | NA | - | - | B44 | C44 | FALSE | NA | N.gonorrhoeae |
| 1712 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ceftibuten | NA | - | - | B45 | C45 | FALSE | NA | N.gonorrhoeae |
| 1713 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ceftobiprole | NA | - | - | B46 | C46 | FALSE | NA | N.gonorrhoeae |
| 1714 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ceftolozane-tazobactam | NA | - | - | B47 | C47 | FALSE | NA | N.gonorrhoeae |
| 1715 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ceftriaxone | NA | 0.125 | 0.125 | B48 | C48 | FALSE | NA | N.gonorrhoeae |
| 1716 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefuroxime iv | NA | - | - | B49 | C49 | FALSE | NA | N.gonorrhoeae |
| 1717 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Cefuroxime oral | NA | - | - | B50 | C50 | FALSE | NA | N.gonorrhoeae |
| 1718 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ertapenem | NA | IE | IE | B56 | C56 | FALSE | NA | N.gonorrhoeae |
| 1719 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Imipenem | NA | IE | IE | B57 | C57 | FALSE | NA | N.gonorrhoeae |
| 1720 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Meropenem | NA | IE | IE | B58 | C58 | FALSE | NA | N.gonorrhoeae |
| 1721 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Meropenem-vaborbactam | NA | IE | IE | B59 | C59 | FALSE | NA | N.gonorrhoeae |
| 1722 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Aztreonam | NA | IE | IE | B64 | C64 | FALSE | NA | N.gonorrhoeae |
| 1723 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ciprofloxacin | NA | 0.03 | 0.06 | B69 | C69 | FALSE | NA | N.gonorrhoeae |
| 1724 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Levofloxacin | NA | IE | IE | B70 | C70 | FALSE | NA | N.gonorrhoeae |
| 1725 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Moxifloxacin | NA | IE | IE | B71 | C71 | FALSE | NA | N.gonorrhoeae |
| 1726 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Nalidixic acid (screen) | NA | NA | NA | B72 | C72 | FALSE | NA | N.gonorrhoeae |
| 1727 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Norfloxacin (uncomplicated UTI only) | NA | - | - | B73 | C73 | FALSE | NA | N.gonorrhoeae |
| 1728 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Ofloxacin | NA | 0.125 | 0.25 | B74 | C74 | FALSE | NA | N.gonorrhoeae |
| 1729 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Amikacin | NA | - | - | B79 | C79 | FALSE | NA | N.gonorrhoeae |
| 1730 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Gentamicin | NA | - | - | B80 | C80 | FALSE | NA | N.gonorrhoeae |
| 1731 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Netilmicin | NA | - | - | B81 | C81 | FALSE | NA | N.gonorrhoeae |
| 1732 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Tobramycin | NA | - | - | B82 | C82 | FALSE | NA | N.gonorrhoeae |
| 1733 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Dalbavancin | NA | - | - | B87 | C87 | FALSE | NA | N.gonorrhoeae |
| 1734 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Oritavancin | NA | - | - | B88 | C88 | FALSE | NA | N.gonorrhoeae |
| 1735 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Teicoplanin | NA | - | - | B89 | C89 | FALSE | NA | N.gonorrhoeae |
| 1736 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Telavancin | NA | - | - | B90 | C90 | FALSE | NA | N.gonorrhoeae |
| 1737 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Vancomycin | NA | - | - | B91 | C91 | FALSE | NA | N.gonorrhoeae |
| 1738 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Azithromycin | NA | Note | Note | B96 | C96 | FALSE | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L. | N.gonorrhoeae |
| 1739 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Clarithromycin | NA | - | - | B97 | C97 | FALSE | NA | N.gonorrhoeae |
| 1740 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Erythromycin | NA | - | - | B98 | C98 | FALSE | NA | N.gonorrhoeae |
| 1741 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Roxithromycin | NA | - | - | B99 | C99 | FALSE | NA | N.gonorrhoeae |
| 1742 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Telithromycin | NA | - | - | B100 | C100 | FALSE | NA | N.gonorrhoeae |
| 1743 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Clindamycin | NA | - | - | B102 | C102 | FALSE | NA | N.gonorrhoeae |
| 1744 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Quinupristin-dalfopristin | NA | - | - | B103 | C103 | FALSE | NA | N.gonorrhoeae |
| 1745 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Doxycycline | NA | IE | IE | B108 | C108 | FALSE | NA | N.gonorrhoeae |
| 1746 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Eravacycline | NA | IE | IE | B109 | C109 | FALSE | NA | N.gonorrhoeae |
| 1747 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Minocycline | NA | IE | IE | B110 | C110 | FALSE | NA | N.gonorrhoeae |
| 1748 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Tetracycline | NA | 0.5 | 1 | B111 | C111 | FALSE | NA | N.gonorrhoeae |
| 1749 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Tigecycline | NA | IE | IE | B112 | C112 | FALSE | NA | N.gonorrhoeae |
| 1750 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Linezolid | NA | - | - | B117 | C117 | FALSE | NA | N.gonorrhoeae |
| 1751 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Tedizolid | NA | - | - | B118 | C118 | FALSE | NA | N.gonorrhoeae |
| 1752 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Chloramphenicol | NA | - | - | B123 | C123 | FALSE | NA | N.gonorrhoeae |
| 1753 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Colistin | NA | - | - | B124 | C124 | FALSE | NA | N.gonorrhoeae |
| 1754 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Daptomycin | NA | - | - | B125 | C125 | FALSE | NA | N.gonorrhoeae |
| 1755 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Fosfomycin iv | NA | - | - | B126 | C126 | FALSE | NA | N.gonorrhoeae |
| 1756 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Fosfomycin oral | NA | - | - | B127 | C127 | FALSE | NA | N.gonorrhoeae |
| 1757 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Fusidic acid | NA | - | - | B128 | C128 | FALSE | NA | N.gonorrhoeae |
| 1758 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Metronidazole | NA | - | - | B129 | C129 | FALSE | NA | N.gonorrhoeae |
| 1759 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Nitrofurantoin (uncomplicated UTI only) | NA | - | - | B130 | C130 | FALSE | NA | N.gonorrhoeae |
| 1760 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Nitroxoline (uncomplicated UTI only) | NA | - | - | B131 | C131 | FALSE | NA | N.gonorrhoeae |
| 1761 | EUCAST 2019 | 9.0 | Clinical Breakpoint Tables v. 9.0 | human | human | MIC | NA | Neisseria gonorrhoeae | Neisseria gonorrhoeae | NA | Rifampicin | NA | - | - | B132 | C132 | FALSE | NA | N.gonorrhoeae |
| The file is too large to be shown. View Raw |